

Bibliography

Note: Numbers in square brackets denote the chapter in which an entry is cited.

- Adler, L., E. Pachtman, R. Franks, et al. 1982. Neurophysiological Evidence for a Defect in Neuronal Mechanisms Involved in Sensory Gating in Schizophrenia. *Biol. Psychiatry* **17**:639–654. [10]
- Albin, R. L., A. B. Young, and J. B. Penney. 1989. The Functional Anatomy of Basal Ganglia Disorders. *Trends Neurosci.* **12**:366–375. [9]
- Alvarez, V. A., D. A. Ridenour, and B. L. Sabatini. 2006. Retraction of Synapses and Dendritic Spines Induced by Off-Target Effects of RNA Interference. *J. Neurosci.* **26**:7820–7825. [10]
- Amat, J., M. V. Baratta, E. Paul, et al. 2005. Medial Prefrontal Cortex Determines How Stressor Controllability Affects Behavior and Dorsal Raphé Nucleus. *Nature Neurosci.* **8**(3):365–371. [12]
- Amir, R. E., I. B. Van den Veyver, M. Wan, et al. 1999. Rett Syndrome Is Caused by Mutations in X-Linked MECP2, Encoding Methyl-CpG-Binding Protein 2. *Nat. Genet.* **23**(2):185–188. [2]
- Amminger, G. P., M. R. Schafer, K. Papageorgiou, et al. 2010. Long-Chain Omega-3 Fatty Acids for Indicated Prevention of Psychotic Disorders: A Randomized, Placebo-Controlled Trial. *Arch. Gen. Psychiatry* **67**(2):146–154. [4]
- Amoroso, M. W., G. F. Croft, D. J. Williams, et al. 2013. Accelerated High-Yield Generation of Limb-Innervating Motor Neurons from Human Stem Cells. *J. Neurosci.* **33**:574–586. [11]
- Anderson, M. H. C., M. R. Munafo, and E. S. J. Robinson. 2013. Investigating the Psychopharmacology of Cognitive Affective Bias in Rats Using an Affective Tone Discrimination Task. *Psychopharmacology* **226**:601–613. [12]
- Anderson, S., and P. Vanderhaeghen. 2014. Cortical Neurogenesis from Pluripotent Stem Cells: Complexity Emerging from Simplicity. *Curr. Opin. Neurobiol.* **27C**:151–157. [10]
- Andreasen, N. C. 1989. The American Concept of Schizophrenia. *Schizophr. Bull.* **15**(4):519–531. [4]
- . 2007. DSM and the Death of Phenomenology in America: An Example of Unintended Consequences. *Schizophr. Bull.* **33**(1):108–112. [4]
- Anney, R., L. Klei, D. Pinto, et al. 2012. Individual Common Variants Exert Weak Effects on the Risk for Autism Spectrum Disorders. *Hum. Mol. Genet.* **21**(21):4781–4492. [2]
- Antal, A., L. Chaieb, V. Moliadze, et al. 2010. Brain-Derived Neurotrophic Factor (BDNF) Gene Polymorphisms Shape Cortical Plasticity in Humans. *Brain Stimul.* **3**:230–237. [10]
- Araki, T., Y. Sasaki, and J. Milbrandt. 2004. Increased Nuclear NAD Biosynthesis and SIRT1 Activation Prevent Axonal Degeneration. *Science* **305**(5686):1010–1013. [7]
- Arguello, P. A., and J. Gogos. 2006. Modeling Madness in Mice: One Piece at a Time. *Neuron* **52**:179–196. [12]
- Arrowsmith, J. 2011. Trial Watch: Phase III and Submission Failures: 2007–2010. *Nat. Rev. Drug Discov.* **10**(2):87. [13]
- Asanuma, K., C. Tang, Y. Ma, et al. 2006. Network Modulation in the Treatment of Parkinson's Disease. *Brain* **12**:2667–2678. [9]

- Asrican, B., G. J. Augustine, K. Berglund, et al. 2013. Next-Generation Transgenic Mice for Optogenetic Analysis of Neural Circuits. *Front. Neural Circuits* **7**:160. [14]
- Atasoy, D., J. N. Betley, H. H. Su, and S. M. Sternson. 2012. Deconstruction of a Neural Circuit for Hunger. *Nature* **488**:172–177. [10]
- Atwal, J. K., Y. Chen, C. Chiu, et al. 2011. A Therapeutic Antibody Targeting BACE1 Inhibits Amyloid-Beta Production *in Vivo*. *Sci. Transl. Med.* **3**(84):84ra43. [7]
- Autism Genome Project Consortium, P. Szatmari, A. D. Paterson, et al. 2007. Mapping Autism Risk Loci Using Genetic Linkage and Chromosomal Rearrangements. *Nat. Genet.* **39**(3):319–328. [4]
- Ayutyanont, N., J. B. Langbaum, S. B. Hendrix, et al. 2014. The Alzheimer's Prevention Initiative Composite Cognitive Test Score: Sample Size Estimates for the Evaluation of Preclinical Alzheimer's Disease Treatments in Presenilin 1 E280a Mutation Carriers. *J. Clin. Psychiatry* **75**(6):652–660. [7]
- Ba, W., J. van der Raadt, and N. Nadif Kasri. 2013. Rho GTPase Signaling at the Synapse: Implications for Intellectual Disability. *Exp. Cell Res.* **319**(15):2368–2374. [2]
- Baddeley, A. 1986. Working Memory. Oxford: Clarendon Press. [12]
- Balleine, B. W., and J. P. O'Doherty. 2010. Human and Rodent Homologies in Action Control: Corticostriatal Determinants of Goal-Directed and Habitual Action. *Neuropharmacology* **35**:48–69. [12]
- Barch, D. M., J. Bustillo, W. Gaebel, et al. 2013. Logic and Justification for Dimensional Assessment of Symptoms and Related Clinical Phenomena in Psychosis: Relevance to DSM-5. *Schizophr. Res.* **150**(1):15–20. [4]
- Bari, A., D. M. Eagle, A. C. Mar, E. S. J. Robinson, and T.W.Robbins. 2009. Dissociable Effects of Noradrenaline, Dopamine, and Serotonin Uptake Blockade on Stop Task Performance in Rats. *Psychopharmacology* **205**:273–283. [12]
- Bari, A., D. E. Theobald, D. Caprioli, et al. 2010. Serotonin Modulates Sensitivity to Reward and Negative Feedback in a Probabilistic Reversal Learning Task in Rats. *Neuropsychopharmacology* **35**(6):1290–1301. [12]
- Barrett, C. E., A. C. Keebaugh, T. H. Ahern, et al. 2013. Variation in Vasopressin Receptor (Avpr1a) Expression Creates Diversity in Behaviors Related to Monogamy in Prairie Voles. *Horm. Behav.* **63**:518–526. [10]
- Bartus, R. T., M. S. Weinberg, and R. J. Samulski. 2014. Parkinson's Disease Gene Therapy: Success by Design Meets Failure by Efficacy. *Mol. Ther.* **22**(3):487–497. [7]
- Bateman, R. J., C. Xiong, T. L. Benzinger, et al. 2012. Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease. *N. Engl. J. Med.* **367**(9):795–804. [6, 7, 9]
- Baudouin, S. J., J. Gaudias, S. Gerharz, et al. 2012. Shared Synaptic Pathophysiology in Syndromic and Nonsyndromic Rodent Models of Autism. *Science* **338**(6103):128–132. [2]
- Bear, M. F., G. Dölen, E. Osterweil, and N. Nagarajan. 2008. Fragile X: Translation in Action. *Neuropsychopharmacology* **33**:84–87. [10, 13]
- Bear, M. F., K. M. Huber, and S. T. Warren. 2004. The mGluR Theory of Fragile X Mental Retardation. *Trends Neurosci.* **27**(7):370–377. [13]
- Beck, H., I. V. Goussakov, A. Lie, C. Helmstaedter, and C. E. Elger. 2000. Synaptic Plasticity in the Human Dentate Gyrus. *J. Neurosci.* **20**:7080–7086. [10]

- Belin, D., A. C. Mar, J. W. J.W. Dalley, T. W. Robbins, and B. J. Everitt. 2008. High Impulsivity Predicts the Switch to Compulsive Cocaine-Taking. *Science* **320**:1352–1355. [12]
- Benabid, A. L., S. Chabardes, J. Mitrofanis, and P. Pollak. 2009. Deep Brain Stimulation of the Subthalamic Nucleus for the Treatment of Parkinson's Disease. *Lancet Neurol.* **8**(1):67–81. [14]
- Benilova, I., E. Karran, and B. De Strooper. 2012. The Toxic Abeta Oligomer and Alzheimer's Disease: An Emperor in Need of Clothes. *Nat. Neurosci.* **15**(3):349–357. [7]
- Benzinger, T. L., T. Blazey, C. R. Jack, Jr., et al. 2013. Regional Variability of Imaging Biomarkers in Autosomal Dominant Alzheimer's Disease. *PNAS* **110**:E4502–E4509. [9]
- Bergman, H., T. Wichmann, B. Karmon, and M. R. DeLong. 1994. The Primate Subthalamic Nucleus. II. Neuronal Activity in the MPTP Model of Parkinsonism. *J. Neurophysiol.* **72**:507–521. [9]
- Bergmann, C., K. Zerres, J. Senderek, et al. 2003. Oligophrenin 1 (OPHN1) Gene Mutation Causes Syndromic X-Linked Mental Retardation with Epilepsy, Rostral Ventricular Enlargement and Cerebellar Hypoplasia. *Brain* **126**(Pt 7):1537–1544. [2]
- Berk, J. L., O. B. Suhr, L. Obici, et al. 2013. Repurposing Diflunisal for Familial Amyloid Polyneuropathy: A Randomized Clinical Trial. *JAMA* **310**(24):2658–2667. [7]
- Berkel, S., C. R. Marshall, B. Weiss, et al. 2010. Mutations in the SHANK2 Synaptic Scaffolding Gene in Autism Spectrum Disorder and Mental Retardation. *Nat. Genet.* **42**(6):489–491. [4]
- Berndt, A., S. Y. Lee, C. Ramakrishnan, and K. Deisseroth. 2014. Structure-Guided Transformation of Channelrhodopsin into a Light-Activated Chloride Channel. *Science* **344**(6182):420–424. [8]
- Bero, A. W., A. Q. Bauer, F. R. Stewart, et al. 2012. Bidirectional Relationship between Functional Connectivity and Amyloid-Beta Deposition in Mouse Brain. *J. Neurosci.* **32**:4334–4340. [9]
- Bero, A. W., P. Yan, J. H. Roh, et al. 2011. Neuronal Activity Regulates the Regional Vulnerability to Amyloid-Beta Deposition. *Nat. Neurosci.* **14**:750–756. [9]
- Berry-Kravis, E., D. Hessl, L. Abbeduto, et al. 2013. Outcome Measures for Clinical Trials in Fragile X Syndrome. *J. Dev. Behav. Pediatr.* **34**:508–522. [10]
- Bersani, F. S., A. Minichino, P. G. Enticott, et al. 2013. Deep Transcranial Magnetic Stimulation as a Treatment for Psychiatric Disorders: A Comprehensive Review. *Eur. J. Psychiatry* **28**:30–39. [10]
- Bertram, L., C. Lange, K. Mullin, et al. 2008. Genome-Wide Association Analysis Reveals Putative Alzheimer's Disease Susceptibility Loci in Addition to APOE. *Am. J. Hum. Genet.* **83**(5):623–632. [7]
- Betancur, C., and J. D. Buxbaum. 2013. SHANK3 Haploinsufficiency: A “Common” but Underdiagnosed Highly Penetrant Monogenic Cause of Autism Spectrum Disorders. *Mol. Autism* **4**(1):17. [4]
- Bezard, E., and S. Przedborski. 2011. A Tale on Animal Models of Parkinson's Disease. *Mov. Disord.* **26**(6):993–1002. [13]
- Bezzina, G., S. Body, T. H. Cheung, et al. 2008. Effect of Disconnecting the Orbital Prefrontal Cortex from the Nucleus Accumbens Core on Inter-Temporal Choice Behavior: A Quantitative Analysis. *Behav. Brain Res.* **191**:272–279. [12]

- Bien-Ly, N., A. K. Gillespie, D. Walker, S. Y. Yoon, and Y. Huang. 2012. Reducing Human Apolipoprotein E Levels Attenuates Age-Dependent Abeta Accumulation in Mutant Human Amyloid Precursor Protein Transgenic Mice. *J. Neurosci.* **32(14)**:4803–4811. [7]
- Biglan, K. M., Y. Zhang, J. D. Long, et al. 2013. Refining the Diagnosis of Huntington Disease: The PREDICT-HD Study. *Front. Aging Neurosci.* **5**:12. [7]
- Bilican, B., A. Serio, S. J. Barmada, et al. 2012. Mutant Induced Pluripotent Stem Cell Lines Recapitulate Aspects of TDP-43 Proteinopathies and Reveal Cell-Specific Vulnerability. *PNAS* **198(15)**:5803–5808. [5]
- . 2013. Comment on “Drug Screening for ALS Using Patient-Specific Induced Pluripotent Stem Cells.” *Sci. Transl. Med.* **5(188)**:188le182. [5]
- Birks, J. 2006. Cholinesterase Inhibitors for Alzheimer’s Disease. *Cochrane Database Syst. Rev.*(1):CD005593. [7]
- Birman, S. 2008. Neurodegeneration: RNA Turns Number One Suspect in Polyglutamine Diseases. *Curr. Biol.* **18(15)**:R659–R661. [5]
- Birrell, J. M., and V. J. Brown. 2000. Medial Frontal Cortex Mediates Perceptual Attentional Set-Shifting in the Rat. *J. Neurosci.* **20**:4320–4324. [12]
- Bishop, D. V. 2010. Which Neurodevelopmental Disorders Get Researched and Why? *PLoS One* **5(11)**:e15112. [2]
- Blennow, K., H. Zetterberg, and A. M. Fagan. 2012. Fluid Biomarkers in Alzheimer Disease. *Cold Spring Harb. Perspect. Med.* **2(9)**:a006221. [13]
- Blennow, K., H. Zetterberg, C. Haass, and T. Finucane. 2013. Semagacestat’s Fall: Where Next for AD Therapies? *Nat. Med.* **19(10)**:1214–1215. [6]
- Bliss, T. V. P., and S. F. Cooke. 2011. Long-Term Potentiation and Long-Term Depression: A Clinical Perspective. *Clinics (Sao Paulo)* **66(Suppl. 1)**:3–17. [10]
- Bloom, D. E., E. T. Cafiero, E. Jané-Llopis, S. Abrahams-Gessel, and L. R. e. a. Bloom. 2011. The Global Economic Burden of Noncommunicable Diseases. Geneva: World Economic Forum. [1]
- Blumensath, T., S. Jbabdi, M. F. Glasser, et al. 2013. Spatially Constrained Hierarchical Parcellation of the Brain with Resting-State fMRI. *Neuroimage* **76**:313–324. [9]
- Boch, J., H. Scholze, S. Schornack, et al. 2009. Breaking the Code of DNA Binding Specificity of TAL-Type III Effectors. *Science* **326**:1509–1512. [8]
- Boissart, C., A. Poulet, P. Georges, et al. 2013. Differentiation from Human Pluripotent Stem Cells of Cortical Neurons of the Superficial Layers Amenable to Psychiatric Disease Modeling and High-Throughput Drug Screening. *Transl. Psychiatry* **3**:e294. [2, 4]
- Bonaglia, M. C., R. Giorda, S. Beri, et al. 2011. Molecular Mechanisms Generating and Stabilizing Terminal 22q13 Deletions in 44 Subjects with Phelan/Mcdermid Syndrome. *PLoS Genet.* **7(7)**:e1002173. [4]
- Bourgeron, T. 2009. A Synaptic Trek to Autism. *Curr. Opin. Neurobiol.* **19(2)**:231–234. [2]
- Boutajangout, A., J. Ingadottir, P. Davies, and E. M. Sigurdsson. 2011. Passive Immunization Targeting Pathological Phospho-Tau Protein in a Mouse Model Reduces Functional Decline and Clears Tau Aggregates from the Brain. *J. Neurochem.* **118(4)**:658–667. [7]
- Boutros, N., G. Zouridakis, and J. Overall. 1991. Replication and Extension of P50 Findings in Schizophrenia. *Clin. Electroencephalogr.* **22**:40–45. [10]
- Boyden, E. S., F. Zhang, E. Bamberg, G. Nagel, and K. Deisseroth. 2005. Millisecond-Timescale, Genetically Targeted Optical Control of Neural Activity. *Nat. Neurosci.* **8(9)**:1263–1268. [8, 10, 14]

- Bozdagi, O., T. Sakurai, D. Papapetrou, et al. 2010. Haploinsufficiency of the Autism-Associated Shank3 Gene Leads to Deficits in Synaptic Function, Social Interaction, and Social Communication. *Mol. Autism* **1**(1):15. [2]
- Brecht, M., R. Naumann, F. Anjum, et al. 2011. The Neurobiology of Etruscan Shrew Active Touch. *Philos. Trans. R. Soc. Lond. B* **366**:3026–3036. [10]
- Brennan, K. J., A. Simone, J. Jou, et al. 2011. Modelling Schizophrenia Using Human Induced Pluripotent Stem Cells. *Nature* **473**:221–225. [11]
- Brier, M. R., J. B. Thomas, A. Z. Snyder, et al. 2012. Loss of Intranetwork and Internetwork Resting State Functional Connections with Alzheimer's Disease Progression. *J. Neurosci.* **32**:8890–8899. [9]
- Briggman, K. L., M. Helmstaedter, and W. Denk. 2011. Wiring Specificity in the Direction-Selectivity Circuit of the Retina. *Nature* **471**(7337):183–188. [8]
- Brockhaus-Dumke, A., R. Mueller, U. Faigle, and J. Klosterkoetter. 2008. Sensory Gating Revisited: Relation between Brain Oscillations and Auditory Evoked Potentials in Schizophrenia. *Schizophr. Res.* **99**:238–249. [10]
- Brown, C. A., M. C. Campbell, M. Karimi, et al. 2012. Dopamine Pathway Loss in Nucleus Accumbens and Ventral Tegmental Area Predicts Apathetic Behavior in MPTP-Lesioned Monkeys. *Exp. Neurol.* **236**:190–197. [9]
- Brown, C. A., M. K. Karimi, L. Tian, et al. 2013. Validation of Midbrain Positron Emission Tomography Measures for Nigrostriatal Neurons in Macaques. *Ann. Neurol.* **74**:602–610. [9, 10]
- Burchell, V. S., D. E. Nelson, A. Sanchez-Martinez, et al. 2013. The Parkinson's Disease-Linked Proteins Fbxo7 and Parkin Interact to Mediate Mitophagy. *Nat. Neurosci.* **16**(9):1257–1265. [5]
- Bussey, T. J., A. Holmes, L. Lyon, et al. 2012. New Translational Assays for Preclinical Modeling of Cognition in Schizophrenia; the Touch-Screen Testing Method for Mice and Rats. *Neuropharmacology* **62**:1191–1203. [12]
- Bussey, T. J., J. L. Muir, and T. W. Robbins. 1994. A Novel Automated Touchscreen Procedure for Assessing Learning in the Rat Using Computer Graphic Stimuli. *Neurosci. Res. Comm.* **15**:103–110. [12]
- Bütefisch, C. M., V. Khurana, L. Kopylev, and L. G. Cohen. 2004. Enhancing Encoding of a Motor Memory in the Primary Motor Cortex by Cortical Stimulation. *J. Neurophysiol.* **91**:2110–2116. [10]
- Button, K. S., J. P. Ioannidis, C. Mokrysz, et al. 2013. Power Failure: Why Small Sample Size Undermines the Reliability of Neuroscience. *Nat. Rev. Neurosci.* **14**(5):365–376. [3]
- Cahan, P., and G. Q. Daley. 2013. Origins and Implications of Pluripotent Stem Cell Variability and Heterogeneity. *Nat. Rev. Mol. Cell. Biol.* **14**:357–368. [11]
- Callaway, E. M. 2008. Transneuronal Circuit Tracing with Neurotropic Viruses. *Curr. Opin. Neurobiol.* **18**:617–623. [10]
- Campbell, C. D., and E. E. Eichler. 2013. Properties and Rates of Germline Mutations in Humans. *Trends Genet.* **29**(10):575–584. [2]
- Campbell, M. C., J. Markham, H. Flores, et al. 2013. Principal Component Analysis of PiB Distribution in Parkinson and Alzheimer Diseases. *Neurology* **81**:520–527. [10]
- Cannon, T. D. 2014. Neurocognitive Growth Charts and Psychosis: Is the Relationship Predictive? *JAMA Psychiatry* **71**(4):361–362. [4]
- Cannon, T. D., K. Cadenhead, B. Cornblatt, et al. 2008. Prediction of Psychosis in Youth at High Clinical Risk: A Multisite Longitudinal Study in North America. *Arch. Gen. Psychiatry* **65**(1):28–37. [4]

- Cao, G., J. Platisa, V. A. Pieribone, et al. 2013. Genetically Targeted Optical Electrophysiology in Intact Neural Circuits. *Cell* **154**:904–913. [10]
- Capitanio, J. P., and M. E. Emborg. 2008. Contributions of Non-Human Primates to Neuroscience Research. *Lancet* **371(9618)**:1126–1135. [13]
- Cardinal, R. N., D. R. Pennicott, C. L. Sugathapala, T. W. Robbins, and B. J. Everitt. 2001. Impulsive Choice Induced in Rats by Lesions of the Nucleus Accumbens Core. *Science* **292**:2499–2501. [12]
- Cardno, A. G., E. J. Marshall, B. Coid, et al. 1999. Heritability Estimates for Psychotic Disorders: The Maudsley Twin Psychosis Series. *Arch. Gen. Psychiatry* **56**:162–168. [8]
- Cardno, A. G., and M. J. Owen. 2014. Genetic Relationships between Schizophrenia, Bipolar Disorder and Schizoaffective Disorder. *Schizophr. Bull.* **40(3)**:504–515. [3]
- Carey, J. R., F. Fregni, and A. Pascual-Leone. 2006. rTMS Combined with Motor Learning Training in Healthy Subjects. *Restor. Neurol. Neurosci.* **24**:191–199. [10]
- Carli, M., J. L. Evenden, and T. W. Robbins. 1985. Depletion of Unilateral Striatal Dopamine Impairs Initiation of Contralateral Actions and Not Sensory Attention. *Nature* **313**:679–682. [12]
- Carlsson, A. 2002. Treatment of Parkinson's with L-DOPA. The Early Discovery Phase, and a Comment on Current Problems. *J. Neural Transm.* **109(5-6)**:777–787. [13]
- Carrion, R. J., and J. L. Patterson. 2012. An Animal Model That Reflects Human Disease: The Common Marmoset (*Callithrix jacchus*). *Curr. Opin. Virol.* **2**:357–362. [8]
- Castner, S. A., P. S. Goldman-Rakic, and G. V. Williams. 2004. Animal Models of Working Memory: Insights for Targeting Cognitive Dysfunction in Schizophrenia. *Psychopharmacology* **174(1)**:111–125. [13]
- Castner, S. A., G. V. Williams, and P. S. Goldman-Rakic. 2000. Reversal of Antipsychotic-Induced Working Memory Deficits by Short-Term Dopamine D1 Receptor Stimulation. *Science* **287(5460)**:2020–2022. [13]
- Caughey, B., and P. T. Lansbury. 2003. Protofibrils, Pores, Fibrils, and Neurodegeneration: Separating the Responsible Protein Aggregates from the Innocent Bystanders. *Annu. Rev. Neurosci.* **26**:267–298. [7]
- Ceaser, A. E., T. E. Goldberg, M. F. Egan, et al. 2008. Set-Shifting Ability and Schizophrenia: A Marker of Clinical Illness or an Intermediate Phenotype? *Biol. Psychiatry* **64**:782–788. [12]
- Cenik, B., C. F. Sephton, B. Kutluk Cenik, J. Herz, and G. Yu. 2012. Progranulin: A Proteolytically Processed Protein at the Crossroads of Inflammation and Neurodegeneration. *J. Biol. Chem.* **287(39)**:32298–32306. [7]
- Cepeda, C., L. Galvan, S. M. Holley, et al. 2013. Multiple Sources of Striatal Inhibition Are Differentially Affected in Huntington's Disease Mouse Models. *J. Neurosci.* **33**:7393–7406. [9]
- Chamberlain, S. R., L. Menzies, A. Hampshire, et al. 2008. Orbitofrontal Dysfunction in Patients with Obsessive-Compulsive Disorder and Their Unaffected Relatives. *Science* **321**:421–422. [12]
- Chamberlain, S. R., U. Müller, A. D. Blackwell, et al. 2006. Neurochemical Modulation of Response Inhibition and Probabilistic Learning in Humans. *Science* **311**:861–863. [12]
- Chanda, S., S. Marro, M. Wernig, and T. C. Südhof. 2013. Neurons Generated by Direct Conversion of Fibroblasts Reproduce Synaptic Phenotype Caused by Autism-Associated Neuroligin-3 Mutation. *PNAS* **110**:16622–16627. [11]

- Chari, S., and I. Dworkin. 2013. The Conditional Nature of Genetic Interactions: The Consequences of Wild-Type Backgrounds on Mutational Interactions in a Genome-Wide Modifier Screen. *PLoS Genet.* **9(8)**:e1003661. [2]
- Chaudhuri, K. R., D. G. Healy, and A. H. Schapira. 2006. Non-Motor Symptoms of Parkinson's Disease: Diagnosis and Management. *Lancet Neurol.* **5(3)**:235–245. [7]
- Cheeran, B., P. Talelli, F. Mori, et al. 2008. A Common Polymorphism in the Brain-Derived Neurotrophic Factor Gene (BDNF) Modulates Human Cortical Plasticity and the Response to rTMS. *J. Physiol.* **586**:5717–5725. [10]
- Chen, H. K., Z. Liu, A. Meyer-Franke, et al. 2012. Small Molecule Structure Correctors Abolish Detrimental Effects of Apolipoprotein E4 in Cultured Neurons. *J. Biol. Chem.* **287(8)**:5253–5266. [7]
- Chen, P. C., B. J. Bhattacharyya, J. Hanna, et al. 2011. Ubiquitin Homeostasis Is Critical for Synaptic Development and Function. *J. Neurosci.* **31(48)**:17505–17513. [5]
- Chen, T., K. Koga, G. Descalzi, et al. 2014a. Postsynaptic Potentiation of Corticospinal Projecting Neurons in the Anterior Cingulate Cortex after Nerve Injury. *Mol. Pain* **10**:33. [10]
- Chen, T., J. S. Lu, Q. Song, et al. 2014b. Pharmacological Rescue of Cortical Synaptic and Network Potentiation in a Mouse Model for Fragile X Syndrome. *Neuropsychopharmacology* **39(8)**:1955–1967. [13]
- Chen, T. W., T. J. Wardill, Y. Sun, et al. 2013. Ultrasensitive Fluorescent Proteins for Imaging Neuronal Activity. *Nature* **499(7458)**:295–300. [8]
- Chen, W. R., S. Lee, K. Kato, et al. 1996. Long-Term Modifications of Synaptic Efficacy in the Human Inferior and Middle Temporal Cortex. *PNAS* **93**:8011–8015. [10]
- Chiba, A. A., R. P. Kesner, and C. J. Gibson. 1997. Memory for Temporal Order of New and Familiar Spatial Location Sequences: Role of the Medial Prefrontal Cortex. *Learn. Mem.* **4**:311–317. [12]
- Chilian, B., H. Abdollahpour, T. Bierhals, et al. 2013. Dysfunction of SHANK2 and CHRNA7 in a Patient with Intellectual Disability and Language Impairment Supports Genetic Epistasis of the Two Loci. *Clin. Genet.* **84(6)**:560–565. [2]
- Chu, C.-P., G.-Y. Zhao, R. Jin, et al. 2014. Properties of 4 Hz Stimulation-Induced Parallel Fiber-Purkinje Cell Presynaptic Long-Term Plasticity in Mouse Cerebellar Cortex *in Vivo*. *Eur. J. Neurosci.* **39**:1624–1631. [10]
- Chung, K., J. Wallace, S. Y. Kim, et al. 2013. Structural and Molecular Interrogation of Intact Biological Systems. *Nature* **497(7449)**:332–337. [8, 10]
- Church, D. M., L. Goodstadt, L. W. Hillier, et al. 2009. Lineage-Specific Biology Revealed by a Finished Genome Assembly of the Mouse. *PLoS Biol.* **7**:e1000112. [10]
- Churchill, G. A., D. C. Airey, H. Allayee, et al. 2004. The Collaborative Cross, a Community Resource for the Genetic Analysis of Complex Traits. *Nat. Genet.* **36**:1133–1137. [8]
- Clapp, W. C., I. J. Kirk, J. P. Hamm, D. Shepherd, and T. J. Teyler. 2005. Induction of LTP in the Human Auditory Cortex by Sensory Stimulation. *Eur. J. Neurosci.* **22**:1135–1140. [10]
- Clarke, H. F., J. W. Dalley, H. S. Crofts, T. W. Robbins, and A. C. Roberts. 2004. Cognitive Inflexibility after Prefrontal Serotonin Depletion. *Science* **304**:878–880. [12]
- Clavaguera, F., H. Akatsu, G. Fraser, et al. 2013. Brain Homogenates from Human Tauopathies Induce Tau Inclusions in Mouse Brain. *PNAS* **110(23)**:9535–9540. [5]

- Clavaguera, F., F. Grueninger, and M. Tolnay. 2014a. Intercellular Transfer of Tau Aggregates and Spreading of Tau Pathology: Implications for Therapeutic Strategies. *Neuropharmacology* **76(Pt A)**:9–15. [5]
- Clavaguera, F., J. Hench, I. Lavenir, et al. 2014b. Peripheral Administration of Tau Aggregates Triggers Intracerebral Tauopathy in Transgenic Mice. *Acta Neuropathol.* **1(1)**:82. [5]
- Clayton, N. S., and A. Dickinson. 1998. Episodic-Like Memory During Cache Recovery by Scrub-Jays. *Nature* **395**:272–274. [12]
- Coelho, T., L. F. Maia, A. Martins da Silva, et al. 2012. Tafamidis for Transthyretin Familial Amyloid Polyneuropathy: A Randomized, Controlled Trial. *Neurology* **79(8)**:785–792. [7]
- Cong, L., F. A. Ran, D. Cox, et al. 2013. Multiplex Genome Engineering Using CRISPR/Cas Systems. *Science* **339**:819–823. [8]
- Cooke, S. F., and M. F. Bear. 2012. Stimulus-Selective Response Plasticity in the Visual Cortex: An Assay for the Assessment of Pathophysiology and Treatment of Cognitive Impairment Associated with Psychiatric Disorders. *Biol. Psychiatry* **71**:487–495. [10]
- Cooper, J. J., and F. Ovsiew. 2013. The Relationship between Schizophrenia and Frontotemporal Dementia. *J. Geriatr. Psychiatry Neurol.* **26(3)**:131–137. [13]
- Corlett, P. R., G. K. Murray, G. D. Honey, et al. 2007. Disrupted Prediction-Error Signal in Psychosis: Evidence for an Associative Account of Delusions. *Brain* **130(9)**:2387–2400. [12]
- Corti, S., M. Nizzardo, C. Simone, et al. 2012. Genetic Correction of Human Induced Pluripotent Stem Cells from Patients with Spinal Muscular Atrophy. *Sci. Transl. Med.* **4**:165ra162. [11]
- Cosentino, G., B. Fierro, P. Paladino, et al. 2012. Transcranial Direct Current Stimulation Preconditioning Modulates the Effect of High-Frequency Repetitive Transcranial Magnetic Stimulation in the Human Motor Cortex. *Eur. J. Neurosci.* **35**:119–124. [10]
- Costa-Mattioli, M., and L. M. Monteggia. 2013. mTOR Complexes in Neurodevelopmental and Neuropsychiatric Disorders. *Nat. Neurosci.* **16(11)**:1537–1543. [2]
- Courtine, G., M. B. Bunge, J. W. Fawcett, et al. 2007. Can Experiments in Nonhuman Primates Expedite the Translation of Treatments for Spinal Cord Injury in Humans? *Nat. Med.* **13(5)**:561–566. [13]
- Craddock, N., M. C. O'Donovan, and M. J. Owen. 2007. Phenotypic and Genetic Complexity of Psychosis. Invited Commentary on Schizophrenia: A Common Disease Caused by Multiple Rare Alleles. *Br. J. Psychiatry* **190**:200–203. [3]
- Craddock, N., and M. J. Owen. 2005. The Beginning of the End for the Kraepelinian Dichotomy. *Br. J. Psychiatry* **186**:364–366. [3]
- . 2010. The Kraepelinian Dichotomy: Going, Going...But Still Not Gone. *Br. J. Psychiatry* **196**:92–95. [3]
- Craddock, N., and P. Sklar. 2013. Genetics of Bipolar Disorder. *Lancet* **381**:1654–1662. [8]
- Cramer, P. E., J. R. Cirrito, D. W. Wesson, et al. 2012. Apoe-Directed Therapeutics Rapidly Clear Beta-Amyloid and Reverse Deficits in AD Mouse Models. *Science* **335(6075)**:1503–1506. [7]
- Criswell, S. R., J. S. Perlmutter, T. O. Videen, et al. 2011. Reduced Uptake of [¹⁸F] FDOPA PET in Asymptomatic Welders with Occupational Manganese Exposure. *Neurology* **76**:1296–1301. [10]

- Cross-Disorder Group of the Psychiatric Genomics, C., S. H. Lee, S. Ripke, et al. 2013. Genetic Relationship between Five Psychiatric Disorders Estimated from Genome-Wide SNPs. *Nat. Genet.* **45(9)**:984–994. [2, 3]
- Cross-Disorder Group of the Psychiatric Genomics Consortium, and Genetic Risk Outcome of Psychosis Consortium. 2013. Identification of Risk Loci with Shared Effects on Five Major Psychiatric Disorders: A Genome-Wide Analysis. *Lancet* **381(9875)**:1371–1379. [4]
- Cuervo, A. M., and E. Wong. 2013. Chaperone-Mediated Autophagy: Roles in Disease and Aging. *Cell Res.* **24**:92–104. [5]
- Cuthbert, B. N. 2014. The RDoC Framework: Facilitating Transition from ICD/DSM to Dimensional Approaches That Integrate Neuroscience and Psychopathology. *World Psychiatry* **13**:28–35. [12]
- Cuthbert, B. N., and T. R. Insel. 2013. Toward the Future of Psychiatric Diagnosis: The Seven Pillars of RDoC. *BMC Med.* **11**:126. [3]
- Czupryn, A., Y. D. Zhou, X. Chen, et al. 2011. Transplanted Hypothalamic Neurons Restore Leptin Signaling and Ameliorate Obesity in db/db Mice. *Science* **334**:1133–1137. [11]
- Dalley, J. W., T. D. Fryer, L. Brichard, et al. 2007. Nucleus Accumbens D2/3 Receptors Predict Trait Impulsivity and Cocaine Reinforcement. *Science* **315**:1267–1270. [12]
- Daniels, A. M., A. K. Halladay, A. Shih, L. M. Elder, and G. Dawson. 2014. Approaches to Enhancing the Early Detection of Autism Spectrum Disorders: A Systematic Review of the Literature. *J. Am. Acad. Child Adolesc. Psychiatry* **53(2)**:141–152. [4]
- Davies, G., A. Tenesa, A. Payton, et al. 2011. Genome-Wide Association Studies Establish That Human Intelligence Is Highly Heritable and Polygenic. *Mol. Psychiatry* **16(10)**:996–1005. [2]
- Davis, M., K. Ressler, B. O. Rothbaum, and R. Richardson. 2006. Effects of D-Cycloserine on Extinction: Translation from Preclinical to Clinical Work. *Biol. Psychiatry* **60**:369–375. [12]
- Deary, I. J., J. Yang, G. Davies, et al. 2012. Genetic Contributions to Stability and Change in Intelligence from Childhood to Old Age. *Nature* **482(7384)**:212–215. [2]
- de Calignon, A., M. Polydoro, M. Suarez-Calvet, et al. 2012. Propagation of Tau Pathology in a Model of Early Alzheimer's Disease. *Neuron* **73(4)**:685–697. [5]
- Deisseroth, K. 2014. Circuit Dynamics of Adaptive and Maladaptive Behaviour. *Nature* **505(7483)**:309–317. [13, 14]
- Deisseroth, K., and M. J. Schnitzer. 2013. Engineering Approaches to Illuminating Brain Structure and Dynamics. *Neuron* **80**:568–577. [10]
- Dell'Mour, V., F. Range, and L. Huber. 2009. Social Learning and Mother's Behavior in Manipulative Tasks in Infant Marmosets. *Am. J. Primatol.* **71**:503–509. [8]
- DeLong, G. R., C. R. Ritch, and S. Burch. 2002. Fluoxetine Response in Children with Autistic Spectrum Disorders: Correlation with Familial Major Affective Disorder and Intellectual Achievement. *Dev. Med. Child Neurol.* **44(10)**:652–659. [4]
- DeLong, G. R., L. A. Teague, and M. McSwain Kamran. 1998. Effects of Fluoxetine Treatment in Young Children with Idiopathic Autism. *Dev. Med. Child Neurol.* **40(8)**:551–562. [4]
- Delorme, R., E. Ey, R. Toro, et al. 2013. Progress toward Treatments for Synaptic Defects in Autism. *Nat. Med.* **19(6)**:685–694. [2]
- Demeule, M., J. C. Currie, Y. Bertrand, et al. 2008. Involvement of the Low-Density Lipoprotein Receptor-Related Protein in the Transcytosis of the Brain Delivery Vector Angioprep-2. *J. Neurochem.* **106(4)**:1534–1544. [7]

- Denny, J. C., L. Nastarache, M. S. Ritchie, et al. 2013. Systematic Comparison of Phenome-Wide Association Study of Electronic Medical Record Data and Genome-Wide Association Study Data. *Nat. Biotechnol.* **31**:1102–1111. [10]
- Dere, E., J. P. Huston, and M. A. D. S. Silva. 2007. The Pharmacology, Neuroanatomy and Neurogenetics of One-Trial Object Recognition in Rodents. *Neurosci. Biobehav. Res.* **31**:673–704. [12]
- De Rubeis, S., X. He, A. P. Goldberg, et al. 2014. Synaptic, Transcriptional and Chromatin Genes Disrupted in Autism. *Nat. Chem. Biol.* **515**:209–215. [1]
- Developmental Disabilities Monitoring Network Surveillance Year Principal Investigators. 2014. Prevalence of Autism Spectrum Disorder among Children Aged 8 Years: Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2010. *MMWR Surveill. Summ.* **63(Suppl 2)**:1–21. [2]
- Dias, R., T. W. Robbins, and A. C. Roberts. 1996. Dissociation in Prefrontal Cortex of Affective and Attentional Shifts. *Nature* **380**:69–72. [12]
- Dickerson, F., C. Stallings, A. Origoni, J. Boronow, and R. Yolken. 2007. Elevated Serum Levels of C-Reactive Protein Are Associated with Mania Symptoms in Outpatients with Bipolar Disorder. *Prog. Neuropsychopharmacol. Biol. Psychiatry* **31(4)**:952–955. [13]
- Diester, I., M. T. Kaufman, M. Mogri, et al. 2011. An Optogenetic Toolbox Designed for Primates. *Nat. Neurosci.* **14**:387–397. [10, 13]
- Di Giorgio, F. P., M. A. Carrasco, M. C. Siao, T. Maniatis, and K. Eggan. 2007. Non-Cell Autonomous Effect of Glia on Motor Neurons in an Embryonic Stem Cell-Based ALS Model. *Nature Neurosci.* **10**:608–614. [11]
- Dimitrov, D., Y. He, H. Mutoh, et al. 2007. Engineering and Characterization of an Enhanced Fluorescent Protein Voltage Sensor. *PLoS One* **2**:e440. [10]
- Dodart, J. C., R. A. Marr, M. Koistinaho, et al. 2005. Gene Delivery of Human Apolipoprotein E Alters Brain Abeta Burden in a Mouse Model of Alzheimer's Disease. *PNAS* **102(4)**:1211–1216. [7]
- Dölen, G., and M. F. Bear. 2009. Fragile X Syndrome and Autism: From Disease Model to Therapeutic Targets. *J. Neurodev. Disord.* **1**:133–140. [10, 13]
- Dölen, G., A. Darvishzadeh, K. W. Huang, and R. C. Malenka. 2013. Social Reward Requires Coordinated Activity of Nucleus Accumbens Oxytocin and Serotonin. *Nature* **501**:179–184. [10]
- Dölen, G., E. Osterweil, B. S. S. Rao, et al. 2007. Correction of Fragile X Syndrome in Mice. *Neuron* **56**:955–962. [10, 13]
- Dong, S., S. C. Rogan, and B. L. Roth. 2010. Directed Molecular Evolution of DREADDs: A Generic Approach to Creating Next-Generation Rassls. *Nat. Protoc.* **5**:561–573. [10]
- Doody, R. S., R. Raman, M. Farlow, et al. 2013. A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease. *N. Engl. J. Med.* **369(4)**:341–350. [6]
- Dubois, B., H. H. Feldman, C. Jacova, et al. 2010. Revising the Definition of Alzheimer's Disease: A New Lexicon. *Lancet Neurol.* **9(11)**:1118–1127. [6]
- Dunnett, S. B. 1985. Comparative Effects of Cholinergic Drugs and Lesions of Nucleus Basalis or Fimbria-Fornix on Delayed Matching in Rats. *Psychopharmacology* **87**:357–363. [12]
- Durand, C. M., C. Betancur, T. M. Boeckers, et al. 2007. Mutations in the Gene Encoding the Synaptic Scaffolding Protein SHANK3 Are Associated with Autism Spectrum Disorders. *Nat. Genet.* **39(1)**:25–27. [2, 4]
- Dutch-Belgian Fragile X Consortium. 1994. Fmr1 Knockout Mice: A Model to Study Fragile X Mental Retardation. *Cell* **78(1)**:23–33. [13]

- Eacott, M. J., A. Easton, and A. Zinkivskay. 2005. Recollection in an Episodic-Like Memory Task in the Rat. *Memory* **12**:221–223. [12]
- Eagle, D. M., and T. W. Robbins. 2003. Lesions of the Medial Prefrontal Cortex or Nucleus Accumbens Core Do Not Impair Inhibitory Control in Rats Performing a Stop-Signal Reaction Time Task. *Behav. Brain Res.* **146**:131–144. [12]
- Ebert, A. D., J. Yu, F. F. Rose, Jr., et al. 2009. Induced Pluripotent Stem Cells from a Spinal Muscular Atrophy Patient. *Nature* **457**:277–280. [11]
- Eiraku, M., K. Watanabe, M. Matsuo-Takasaki, et al. 2008. Self-Organized Formation of Polarized Cortical Tissues from ESCs and Its Active Manipulation by Extrinsic Signals. *Cell Stem Cell* **3**:519–532. [8]
- Elliott, R., B. J. Sahakian, A. P. McKay, et al. 1996. Neuropsychological Impairments in Unipolar Depression: The Influence of Perceived Failure on Subsequent Performance. *Psychol. Med.* **26**:975–989. [12]
- Emre, M., D. Aarsland, A. Albanese, et al. 2004. Rivastigmine for Dementia Associated with Parkinson's Disease. *N. Engl. J. Med.* **351(24)**:2509–2518. [13]
- Engle, S. J., and D. Puppala. 2013. Integrating Human Pluripotent Stem Cells into Drug Development. *Cell Stem Cell* **12**:669–677. [11]
- Enkel, T., D. Gholizadeh, U. von Bohlen, et al. 2010. Ambiguous Cue Interpretation Is Biased under Stress- and Depression-Like States in Rats. *Neuropsychopharmacology* **35**:1008–1015 [12]
- Ennaceur, A., and J. Delacour. 1988. A New One-Trial Test for Neurobiological Studies of Memory in Rats. I: Behavioral Data. *Behav. Brain Res.* **31**:47–59. [12]
- Ennis, L., and T. Wykes. 2013. Impact of Patient Involvement in Mental Health Research: Longitudinal Study. *Br. J. Psychiatry* **203(5)**:381–386. [4]
- Ersche, K. D., P. S. Jones, G. B. Williams, et al. 2012. Abnormal Brain Structure Implicated in Stimulant Drug Addiction. *Science* **335**:601–604. [12]
- Espuny-Camacho, I., K. A. Michelsen, D. Gall, et al. 2013. Pyramidal Neurons Derived from Human Pluripotent Stem Cells Integrate Efficiently into Mouse Brain Circuits *in Vivo*. *Neuron* **77**:440–456. [11]
- Evenden, J. L. 1999. Varieties of Impulsivity. *Psychopharmacology* **146**:348–361. [12]
- Everitt, B. J., and T. W. Robbins. 1997. Central Cholinergic Systems and Cognition. *Annu. Rev. Psychol.* **48**:649–684. [13]
- Everitt, B. J., and T. W. Robbins. 2005. Neural Systems of Reinforcement for Drug Addiction: From Actions to Habits to Compulsion. *Nature Neurosci.* **8**:1481–1489. [12]
- Ey, E., C. S. Leblond, and T. Bourgeron. 2011. Behavioral Profiles of Mouse Models for Autism Spectrum Disorders. *Autism Res.* **4(1)**:5–16. [2]
- Fagan, A. M., M. A. Mintun, R. H. Mach, et al. 2006. Inverse Relation between *in Vivo* Amyloid Imaging Load and Cerebrospinal Fluid Abeta42 in Humans. *Ann. Neurol.* **59(3)**:512–519. [7]
- Fernandez, F., W. Morishita, E. Zuniga, et al. 2007. Pharmacotherapy for Cognitive Impairment in a Mouse Model of Down Syndrome. *Nat. Neurosci.* **10(4)**:411–413. [7]
- Fernando, A. B., and T. W. Robbins. 2011. Animal Models of Neuropsychiatric Disorders. *Ann. Rev. Clin. Psychol.* **7**:39–61. [12]
- Figurov, A., L. D. Pozz-Miller, P. Olafsson, T. Wang, and B. Lu. 1996. Regulation of Synaptic Responses to High-Frequency Stimulation and LTP by Neurotrophins in the Hippocampus. *Nature* **381**:706–709. [10]
- Flannick, J., G. Thorleifsson, N. L. Beer, et al. 2014. Loss-of-Function Mutations in Slc30a8 Protect against Type 2 Diabetes. *Nat. Genet.* **46(4)**:357–363. [2, 4]

- Fontes, A., and U. Lakshmiopathy. 2013. Advances in Genetic Modification of Pluripotent Stem Cells. *Biotechnol. Adv.* **31**:994–1001. [8]
- Foust, K. D., E. Nurre, C. L. Montgomery, et al. 2009. Intravascular AAV9 Preferentially Targets Neonatal-Neurons and Adult-Astrocytes in CNS. *Nat. Biotechnol.* **27**:59–65. [10]
- Fox, M. D., M. A. Halko, M. C. Eldaief, and A. Pascual-Leone. 2012. Measuring and Manipulating Brain Connectivity with Resting State Functional Connectivity Magnetic Resonance Imaging (fcMRI) and Transcranial Magnetic Stimulation (TMS). *Neuroimage* **62**(4):2232–2243. [13]
- Frank, S. A. 2014. Somatic Mosaicism and Disease. *Curr. Biol.* **24**(12):R577–R581. [2]
- Freitas, C., F. Farzan, and A. Pascual-Leone. 2013. Assessing Brain Plasticity across the Lifespan with Transcranial Magnetic Stimulation: Why, How, and What Is the Ultimate Goal? *Front. Neurosci.* **7**:42. [13]
- Freund, P., E. Schmidlin, T. Wannier, et al. 2006. NoGo: A-Specific Antibody Treatment Enhances Sprouting and Functional Recovery after Cervical Lesion in Adult Primates. *Nat. Med.* **12**(7):790–792. [13]
- Fritsch, B., J. Reis, K. Martinowich, et al. 2010. Direct Current Stimulation Promotes BDNF-Dependent Synaptic Plasticity: Potential Implications for Motor Learning. *Neuron* **66**:198–204. [10]
- Frodl, T., J. Scheuerecker, V. Schoepf, et al. 2011. Different Effects of Mirtazapine and Venlafaxine on Brain Activation: An Open Randomized Controlled fMRI Study. *J. Clin. Psychiatry* **72**:448–457. [10]
- Fromer, M., A. J. Pocklington, D. H. Kavanagh, et al. 2014. *De Novo* Mutations in Schizophrenia Implicate Synaptic Networks. *Nature* **506**(7487):179–184. [3, 4]
- Frost, B., and M. I. Diamond. 2010. Prion-Like Mechanisms in Neurodegenerative Diseases. *Nat. Rev. Neurosci.* **11**(3):155–159. [7]
- Fusar-Poli, P., S. Borgwardt, A. Bechdolf, et al. 2013. The Psychosis High-Risk State: A Comprehensive State-of-the-Art Review. *JAMA Psychiatry* **70**(1):107–120. [4]
- Gaffan, D., R. C. Saunders, E. A. Gaffan, et al. 1984. Effects of Fornix Transection Upon Associative Memory in Monkeys: Role of the Hippocampus in Learned Action. *Q. J. Exp. Psychol. B* **36**:173–227. [12]
- Gafni, O., L. Weinberger, A. A. Mansour, et al. 2013. Derivation of Novel Human Ground State Naive Pluripotent Stem Cells. *Nature* **504**(7479):282–286. [13]
- Galvan, A., X. Hu, Y. Smith, and T. Wichmann. 2012. *In Vivo* Optogenetic Control of Striatal and Thalamic Neurons in Non-Human Primates. *PLoS One* **7**:e50808. [10]
- Gantois, I., A. S. Pop, C. E. de Esch, et al. 2013. Chronic Administration of AFQ056/Mavoglurant Restores Social Behaviour in Fmr1 Knockout Mice. *Behav. Brain Res.* **239**:72–79. [13]
- Gaskin, P. L., S. P. Alexander, and K. C. Fone. 2014. Neonatal Phencyclidine Administration and Post-Weaning Social Isolation as a Dual-Hit Model of “Schizophrenia-Like” Behaviour in the Rat. *Psychopharmacology* **231**(12):2533–2545. [13]
- Gastambide, F., M. C. Cotel, G. Gilmour, et al. 2012. Selective Remediation of Reversal Learning Deficits in the Neurodevelopmental MAM Model of Schizophrenia by a Novel Mglu5 Positive Allosteric Modulator. *Neuropsychopharmacology* **37**(4):1057–1066. [13]
- Gatev, P., and T. Wichmann. 2009. Interactions between Cortical Rhythms and Spiking Activity of Single Basal Ganglia Neurons in the Normal and Parkinsonian State. *Cereb. Cortex* **19**:1330–1344. [9]

- Geyer, M. A., K. Krebs-Thomson, D. L. Braff, and N. R. Swerdlow. 2001. Pharmacological Studies of Prepulse Inhibition Models of Sensorimotor Gating Deficits in Schizophrenia: A Decade in Review. *Psychopharmacology* **156**:117–154. [12]
- Gilissen, C., J. Y. Hehir-Kwa, D. T. Thung, et al. 2014. Genome Sequencing Identifies Major Causes of Severe Intellectual Disability. *Nature* **511(7509)**:344–347. [2]
- Gillberg, C. 2010. The ESSENCE in Child Psychiatry: Early Symptomatic Syndromes Eliciting Neurodevelopmental Clinical Examinations. *Res. Dev. Disabil.* **31(6)**:1543–1551. [2]
- Giovanoli, S., H. Engler, A. Engler, et al. 2013. Stress in Puberty Unmasks Latent Neuropathological Consequences of Prenatal Immune Activation in Mice. *Science* **339(6123)**:1095–1099. [13]
- Girirajan, S., J. A. Rosenfeld, B. P. Coe, et al. 2012. Phenotypic Heterogeneity of Genomic Disorders and Rare Copy-Number Variants. *N. Engl. J. Med.* **367(14)**:1321–1331. [2]
- Girirajan, S., J. A. Rosenfeld, G. M. Cooper, et al. 2010. A Recurrent 16p12.1 Microdeletion Supports a Two-Hit Model for Severe Developmental Delay. *Nat. Genet.* **42(3)**:203–209. [2]
- Giusti-Rodríguez, P., and P. F. Sullivan. 2013. The Genomics of Schizophrenia: Update and Implications. *J. Clin. Invest.* **123**:4557–4563. [8]
- Glass, C. K., K. Saijo, B. Winner, M. C. Marchetto, and F. H. Gage. 2010. Mechanisms Underlying Inflammation in Neurodegeneration. *Cell* **140(6)**:918–934. [5]
- Goetghebuer, P., and R. Dias. 2008. Comparison of Haloperidol, Risperidone, Sertindole, and Modafinil to Reverse an Attentional Set-Shifting Impairment Following Subchronic Pcp Administration in the Rat: A Back Translational Study. *Psychopharmacology* **202**:202. [12]
- Gokhale, A., J. Larimore, E. Werner, et al. 2012. Quantitative Proteomic and Genetic Analyses of the Schizophrenia Susceptibility Factor Dysbindin Identify Novel Roles of the Biogenesis of Lysosome-Related Organelles Complex 1. *J. Neurosci.* **32(11)**:3697–3711. [2]
- Golde, T. E., L. S. Schneider, and E. H. Koo. 2011. Anti-Abeta Therapeutics in Alzheimer's Disease: The Need for a Paradigm Shift. *Neuron* **69(2)**:203–213. [6]
- Goldman-Rakic, P. S. 1996. The Prefrontal Landscape: Implications of Functional Architecture for Understanding Human Mentation and the Central Executive. In: *The Prefrontal Cortex*, ed. A. C. Roberts et al., pp. 87–102. Oxford: Oxford Univ. Press. [12]
- Goldman-Rakic, P. S., S. A. Castner, T. H. Svensson, L. J. Siever, and G. V. Williams. 2004. Targeting the Dopamine D1 Receptor in Schizophrenia: Insights for Cognitive Dysfunction. *Psychopharmacology* **174(1)**:3–16. [13]
- Goldsworthy, M. R., J. B. Pitcher, and M. C. Ridding. 2012. The Application of Spaced Theta Burst Protocols Induces Long-Lasting Neuroplastic Changes in the Human Motor Cortex. *Eur. J. Neurosci.* **35**:125–134. [10]
- Goodin, D. S., and D. Bates. 2009. Treatment of Early Multiple Sclerosis: The Value of Treatment Initiation after a First Clinical Episode. *Mult. Scler.* **15(10)**:1175–1182. [6]
- Gottesman, I. I., and T. D. Gould. 2003. The Endophenotype Concept in Psychiatry: Etymology and Strategic Intentions. *Am. J. Psychiatry* **160(4)**:636–645. [12]
- Grabrucker, A. M., M. J. Schmeisser, M. Schoen, and T. M. Boeckers. 2011. Postsynaptic ProSAP/Shank Scaffolds in the Cross-Hair of Synaptopathies. *Trends Cell. Biol.* **21(10)**:594–603. [4, 10]

- Gradinaru, V., M. Mogri, K. R. Thompson, J. M. Henderson, and K. Deisseroth. 2009. Optical Deconstruction of Parkinsonian Neural Circuitry. *Sci. Transl. Med.* **324**:354–359. [9]
- Graf, T. 2011. Historical Origins of Transdifferentiation and Reprogramming. *Cell Stem Cell* **9(6)**:504–516. [13]
- Granger, A. J., and R. A. Nicoll. 2014. Expression Mechanisms Underlying Long-Term Potentiation: A Postsynaptic View, 10 Years on. *Philos. Trans. R. Soc. Lond. B* **369(1633)**:20130136. [10]
- Grant, S. G., M. C. Marshall, K. L. Page, M. A. Cumiskey, and J. D. Armstrong. 2005. Synapse Proteomics of Multiprotein Complexes: en Route from Genes to Nervous System Diseases. *Hum. Mol. Genet.* **14(2)**:R225–R234. [3, 4]
- Gratten, J., N. R. Wray, M. C. Keller, and P. M. Visscher. 2014. Large-Scale Genomics Unveils the Genetic Architecture of Psychiatric Disorders. *Nat. Neurosci.* **17(6)**:782–790. [2]
- Graves, A. R., S. J. Moore, E. B. Bloss, et al. 2012. Hippocampal Pyramidal Neurons Comprise Two Distinct Cell Types That Are Countermodulated by Metabotropic Receptors. *Neuron* **76**:776–789. [10]
- Graybiel, A. M. 2008. Habits, Rituals, and the Evaluative Brain. *Annu. Rev. Neurosci.* **31**:359–387. [8]
- Green, E. K., D. Grozeva, I. Jones, et al. 2010. The Bipolar Disorder Risk Allele at CACNA1C Also Confers Risk of Recurrent Major Depression and of Schizophrenia. *Mol. Psychiatry* **15(10)**:1016–1022. [3]
- Green, M. F., P. D. Butler, Y. Chen, et al. 2009. Perception Measurement in Clinical Trials of Schizophrenia: Promising Paradigms from CNTRICS. *Schizophr. Bull.* **35**:163–181. [12]
- Greicius, M. D. 2008. Resting-State Functional Connectivity in Neuropsychiatric Disorders. *Curr. Opin. Neurol.* **21**:424–430. [10]
- Greicius, M. D., G. Srivastava, A. L. Reiss, and V. Menon. 2004. Default-Mode Network Activity Distinguishes Alzheimer's Disease from Healthy Aging: Evidence from Functional MRI. *PNAS* **101(13)**:4637–4642. [7]
- Grimm, D., J. S. Lee, L. Wang, et al. 2008. *In Vitro* and *in Vivo* Gene Therapy Vector Evolution via Multispecies Interbreeding and Retargeting of Adeno-Associated Viruses. *J. Virol.* **82**:5887–5911. [10]
- Grozeva, D., G. Kirov, D. F. Conrad, et al. 2013. Reduced Burden of Very Large and Rare CNVs in Bipolar Affective Disorder. *Bipolar Dis.* **15(8)**:893–898. [3]
- Grozeva, D., G. Kirov, D. Ivanov, et al. 2010. Rare Copy Number Variants: A Point of Rarity in Genetic Risk for Bipolar Disorder and Schizophrenia. *Arch. Gen. Psychiatry* **67**:318–327. [3]
- Guerreiro, R., A. Wojtas, J. Bras, et al. 2013. TREM2 Variants in Alzheimer's Disease. *N. Engl. J. Med.* **368(2)**:117–127. [7]
- Guilfoyle, D. N., S. V. Gerum, J. L. Sanchez, et al. 2013. Functional Connectivity fMRI in Mouse Brain at 7t Using Isoflurane. *J. Neurosci. Meth.* **214**:144–148. [9]
- Guilmatre, A., G. Huguette, R. Delorme, and T. Bourgeron. 2014. The Emerging Role of Shank Genes in Neuropsychiatric Disorders. *Dev. Neurobiol.* **74(2)**:113–122. [4]
- Gulsuner, S., T. Walsh, A. C. Watts, et al. 2013. Spatial and Temporal Mapping of *de Novo* Mutations in Schizophrenia to a Fetal Prefrontal Cortical Network. *Cell* **154**:518–529. [10]
- Guo, Z., L. Zhang, Z. Wu, et al. 2014. *In Vivo* Direct Reprogramming of Reactive Glial Cells into Functional Neurons after Brain Injury in an Alzheimer's Disease Model. *Cell Stem Cell* **14**:188–202. [11]

- Gur, R. C., M. E. Calkins, T. D. Satterthwaite, et al. 2014. Neurocognitive Growth Charting in Psychosis Spectrum Youths. *JAMA Psychiatry* **71(4)**:366–374. [4]
- Haber, S. N., and B. Knutson. 2010. The Reward Circuit: Linking Primate Anatomy to Human Imaging. *Neuropsychopharmacol. Rev.*:4–26. [12]
- Hacker, C. D., J. S. Perlmutter, S. R. Criswell, B. M. Ances, and A. Z. Snyder. 2012. Resting State Functional Connectivity of the Striatum in Parkinson's Disease. *Brain* **135**:3699–3711. [9]
- Hall, E. L., S. E. Robson, P. G. Morris, and M. J. Brookes. 2013. The Relationship between MEG and fMRI. *Neuroimage* **102(Pt 1)**:80–91. [9]
- Hall, F. S., L. S. Wilkinson, T. Humby, et al. 1998. Isolation Rearing in Rats: Pre- and Postsynaptic Changes in Striatal Dopaminergic Systems. *Pharmacol. Biochem. Behav.* **59(4)**:859–872. [13]
- Hall, M.-H., G. Taylor, P. Sham, et al. 2011. The Early Auditory Gamma-Band Response Is Heritable and a Putative Endophenotype of Schizophrenia. *Schizophr. Bull.* **37**:778–787. [10]
- Hamasaki, M., N. Furuta, A. Matsuda, et al. 2013. Autophagosomes Form at ER-Mitochondria Contact Sites. *Nature* **495(7441)**:389–393. [5]
- Han, K., J. L. Holder, Jr., C. P. Schaaf, et al. 2013a. SHANK3 Overexpression Causes Manic-Like Behaviour with Unique Pharmacogenetic Properties. *Nature* **503(7474)**:72–77. [2, 4]
- Han, X., M. Chen, F. Wang, et al. 2013b. Forebrain Engraftment by Human Glial Progenitor Cells Enhances Synaptic Plasticity and Learning in Adult Mice. *Cell Stem Cell* **12(3)**:342–353. [13]
- Hanlon, F. M., M. P. Weisend, and D. A. Hamilton. 2006. Impairment on the Hippocampal-Dependent Virtual Morris Water Task in Schizophrenia. *Schizophr. Res.* **87**:67–80. [12]
- Haqqani, A. S., N. Caram-Salas, W. Ding, et al. 2013. Multiplexed Evaluation of Serum and CSF Pharmacokinetics of Brain-Targeting Single-Domain Antibodies Using a NanoLC-SRM-ILIS Method. *Molec. Pharm.* **10(5)**:1542–1556. [7]
- Hara, T., K. Nakamura, M. Matsui, et al. 2006. Suppression of Basal Autophagy in Neural Cells Causes Neurodegenerative Disease in Mice. *Nature* **441(7095)**:885–889. [5]
- Harding, E. J., E. S. Paul, and M. Mendl. 2004. Animal Behavior: Cognitive Bias and Affective State. *Nature* **427**:312–312. [12]
- Hayden, E. Y., and D. B. Teplow. 2013. Amyloid Beta-Protein Oligomers and Alzheimer's Disease. *Alzheimers Res. Ther.* **5(6)**:60. [7]
- Hayhurst, M., A. Wagner, M. Cerletti, A. J. Wagers, and L. L. Rubin. 2012. A Cell-Autonomous Defect in Skeletal Muscle Satellite Cells Expressing Low Levels of Survival of Motor Neuron Protein. *Devel. Biol.* **368**:323–334. [11]
- Hayworth, K. J., N. Kasthuri, R. Schalek, and J. W. Lichtman. 2006. Automating the Collection of Ultrathin Serial Sections for Large Volume TEM Reconstructions. *Microsc. Microanal.* **12(S02)**:86–87. [8]
- Heckers, S. 2008. Making Progress in Schizophrenia Research. *Schizophr. Bull.* **34(4)**:591–594. [4]
- Heiman, M., A. Schaefer, S. Gong, et al. 2008. A Translational Profiling Approach for the Molecular Characterization of CNS Cell Types. *Cell* **135(4)**:738–748. [7]
- Heiman-Patterson, T. D., R. B. Sher, E. A. Blankenhorn, et al. 2011. Effect of Genetic Background on Phenotype Variability in Transgenic Mouse Models of Amyotrophic Lateral Sclerosis: A Window of Opportunity in the Search for Genetic Modifiers. *Amyotroph. Lateral Scler.* **12**:79–86. [9]

- Helmich, R. C., L. C. Derikx, M. Bakker, et al. 2009. Spatial Remapping of Cortico-Striatal Connectivity in Parkinson's Disease. *Cereb. Cortex* **20(5)**:1175–1186. [9]
- Heneka, M. T., M. P. Kummer, A. Stutz, et al. 2013. NLRP3 Is Activated in Alzheimer's Disease and Contributes to Pathology in APP/PS1 Mice. *Nature* **493(7434)**:674–678. [7]
- Hershey, T., K. J. Black, J. L. Carl, and J. S. Perlmutter. 2000. Dopa-Induced Blood Flow Responses in Non-Human Primates. *Exp. Neurol.* **166**:342–349. [9]
- Hertz, N. T., A. Berthet, M. L. Sos, et al. 2013. A Neo-Substrate That Amplifies Catalytic Activity of Parkinson's-Disease-Related Kinase PINK1. *Cell* **154(4)**:737–747. [5]
- Hnasko, T. S., F. A. Perez, A. D. Scouras, et al. 2006. Cre Recombinase-Mediated Restoration of Nigrostriatal Dopamine in Dopamine-Deficient Mice Reverses Hypophagia and Bradykinesia. *PNAS* **103**:8858–8863. [10]
- Ho, B. C., M. Flaum, W. Hubbard, S. Arndt, and N. C. Andreasen. 2004. Validity of Symptom Assessment in Psychotic Disorders: Information Variance across Different Sources of History. *Schizophr. Res.* **68(2-3)**:299–307. [4]
- Hoff, P. 1985. Zum Krankheitsbegriff Bei Emil Kraepelin (Concept of Disease of Emil Kraepelin). *Nervenarzt* **56(9)**:510–513. [4]
- Hoffman, S. G., J. Q. Wu, and H. Boettcher. 2013. D-Cycloserine as an Augmentation Strategy for Cognitive Behavioral Therapy of Anxiety Disorders. *Biol. Mood Anxiety Disord.* **3**:11. [12]
- Hoischen, A., N. Krumm, and E. E. Eichler. 2014. Prioritization of Neurodevelopmental Disease Genes by Discovery of New Mutations. *Nat. Neurosci.* **17(6)**:764–772. [2]
- Holland, D., L. K. McEvoy, and A. M. Dale. 2012. Unbiased Comparison of Sample Size Estimates from Longitudinal Structural Measures in ADNI. *Hum. Brain Mapping* **33(11)**:2586–2602. [6]
- Hollingworth, P., D. Harold, R. Sims, et al. 2011. Common Variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP Are Associated with Alzheimer's Disease. *Nat. Genet.* **43(5)**:429–435. [7]
- Holmes, C., D. Boche, D. Wilkinson, et al. 2008. Long-Term Effects of Abeta42 Immunisation in Alzheimer's Disease: Follow-up of a Randomised, Placebo-Controlled Phase I Trial. *Lancet* **3372(9634)**:216–223. [6]
- Holtzman, D. M., J. Herz, and G. Bu. 2012. Apolipoprotein E and Apolipoprotein E Receptors: Normal Biology and Roles in Alzheimer Disease. *Cold Spring Harb. Perspect. Med.* **2(3)**:a006312. [7]
- Holtzman, D. M., J. C. Morris, and A. M. Goate. 2011. Alzheimer's Disease: The Challenge of the Second Century. *Sci. Transl. Med.* **3(77)**:77sr71. [6, 7]
- Hong, L. E., A. Summerfelt, B. D. Mitchell, et al. 2008. Sensory Gating Endophenotype Based on Its Neural Oscillatory Pattern and Heritability Estimate. *Arch. Gen. Psychiatry* **65**:1008–1016. [10]
- Hood, L., and S. H. Friend. 2011. Predictive, Personalized, Preventive, Participatory (P4) Cancer Medicine. *Nat. Rev. Clin. Oncol.* **8(3)**:184–187. [2]
- Hoon, M., T. Soykan, B. Falkenburger, et al. 2011. Neuroligin-4 Is Localized to Glycinergic Postsynapses and Regulates Inhibition in the Retina. *PNAS* **108**:3053–3058. [10]
- Hornykiewicz, O., and W. Birkmayer. 1961. Biochemisch-Pharmakologische Grundlagen für Die Klinische Anwendung Von L-Dioxyphenylalanin Beim Parkinson-Syndrom. *Wien Klein. Wochenschr.* **73**:839–840. [9]
- Howes, O. D., A. J. Montgomery, M. C. Asselin, et al. 2009. Elevated Striatal Dopamine Function Linked to Prodromal Signs of Schizophrenia. *Arch. Gen. Psychiatry* **66(1)**:13–20. [13]

- Howes, O. D., and R. M. Murray. 2014. Schizophrenia: An Integrated Sociodevelopmental-Cognitive Model. *Lancet* **383(9929)**:1677–1687. [3]
- Hsu, P. D., E. S. Lander, and F. Zhang. 2014. Development and Applications of CRISPR-Cas9 for Genome Engineering. *Cell* **157**:1262–1278. [8]
- Huang, Y., and L. Mucke. 2012. Alzheimer Mechanisms and Therapeutic Strategies. *Cell* **148**:1204–1222. [5]
- Huber, K. M., S. M. Gallagher, S. T. Warren, and M. F. Bear. 2002. Altered Synaptic Plasticity in a Mouse Model of Fragile X Mental Retardation. *PNAS* **99(11)**:7746–7750. [13]
- Hudry, E., J. Dashkoff, A. D. Roe, et al. 2013. Gene Transfer of Human *ApoE* Isoforms Results in Differential Modulation of Amyloid Deposition and Neurotoxicity in Mouse Brain. *Sci. Transl. Med.* **5(212)**:212ra161. [7]
- Huguet, G., E. Ey, and T. Bourgeron. 2013. The Genetic Landscapes of Autism Spectrum Disorders. *Annu. Rev. Hum. Genet.* **14**:191–213. [2, 4]
- Hulme, S. R., O. D. Jones, and W. C. Abraham. 2013. Emerging Roles of Metaplasticity in Behaviour and Disease. *Trends Neurosci.* **36**:353–362. [10]
- Hung, A. Y., K. Futai, C. Sala, et al. 2008. Smaller Dendritic Spines, Weaker Synaptic Transmission, but Enhanced Spatial Learning in Mice Lacking Shank1. *J. Neurosci.* **28(7)**:1697–1708. [4]
- Hurd, M. D., P. Martorell, A. Delavande, K. J. Mullen, and K. M. Langa. 2013. Monetary Costs of Dementia in the United States. *N. Engl. J. Med.* **368**:1326–1334. [7]
- Hutchison, R. M., and S. Everling. 2012. Monkey in the Middle: Why Non-Human Primates Are Needed to Bridge the Gap in Resting-State Investigations. *Front. Neuroanat.* **6**:29. [9]
- Hutchison, R. M., T. Womelsdorf, E. A. Allen, et al. 2013. Dynamic Functional Connectivity: Promise, Issues, and Interpretations. *Neuroimage* **80**:360–378. [9]
- Hutton, M., C. L. Lendon, P. Rizzu, et al. 1998. Association of Missense and 5'-Splice-Site Mutations in Tau with the Inherited Dementia FTDP-17. *Nature* **393(6686)**:702–705. [13]
- Hyman, S. E. 2010. The Diagnosis of Mental Disorders: The Problem of Reification. *Annu. Rev. Clin. Psychol.* **6**:155–179. [3, 14]
- . 2012. Revolution Stalled. *Transl. Med.* **4(155)**:155cm111. [14]
- . 2014. Revitalizing Psychiatric Therapeutics. *Neuropsychopharmacology* **39**:220–229. [1, 11]
- Iadecola, C. 2004. Neurovascular Regulation in the Normal Brain and in Alzheimer's Disease. *Nature Neurosci.* **5**:347–360. [7]
- Illiff, J. J., M. Wang, Y. Liao, et al. 2012. A Paravascular Pathway Facilitates CSF Flow through the Brain Parenchyma and the Clearance of Interstitial Solutes, Including Amyloid β . *Sci. Transl. Med.* **4(147)**:147ra111. [5, 7]
- Imaizumi, Y., and H. Okano. 2014. Modeling Human Neurological Disorders with Induced Pluripotent Stem Cells. *J. Neurochem.* **129**:388–399. [8]
- Institute of Medicine. 2013. Neurodegeneration: Exploring Commonalities across Diseases. Workshop Summary. Washington, D.C.: National Academies Press. [5]
- International Schizophrenia Consortium, S. M. Purcell, N. R. Wray, et al. 2009. Common Polygenic Variation Contributes to Risk of Schizophrenia and Bipolar Disorder. *Nature* **460(7256)**:748–752. [3]
- Ioannidis, J. P. 2005. Why Most Published Research Findings Are False. *PloS Med.* **2(8)**:e124. [6]
- Iossifov, I., M. Ronemus, D. Levy, et al. 2012. *De Novo* Gene Disruptions in Children on the Autistic Spectrum. *Neuron* **74(2)**:285–299. [2]

- Irwin, I., L. E. DeLanney, L. S. Forno, et al. 1990. The Evolution of Nigrostriatal Neurochemical Changes in the MPTP-Treated Squirrel Monkey. *Brain Res.* **531**:242–252. [9]
- Irwin, S. 1968. Comprehensive Observational Assessment: Ia. A Systematic, Quantitative Procedure for Assessing the Behavioral and Physiologic State of the Mouse. *Psychopharmacology* **13**:222–257. [12]
- Jack, C. R., Jr., and D. M. Holtzman. 2013. Biomarker Modeling of Alzheimer's Disease. *Neuron* **80**(6):1347–1358. [7, 14]
- Jamain, S., H. Quach, C. Betancur, et al. 2003. Mutations of the X-Linked Genes Encoding Neuroligins NLGN3 and NLGN4 Are Associated with Autism. *Nat. Genet.* **34**(1):27–29. [2, 4]
- Jamain, S., K. Radyushkin, K. Hammerschmidt, et al. 2008. Reduced Social Interaction and Ultrasonic Communication in a Mouse Model of Monogenic Heritable Autism. *PNAS* **105**(5):1710–1715. [2]
- Javitt, D. C., A. Shelley, and W. Ritter. 2000. Associated Deficits in Mismatch Negativity Generation and Tone Matching in Schizophrenia. *Clin. Neurophysiol.* **111**:1733–1737. [10]
- Jenner, P. 2003. The Contribution of the MPTP-Treated Primate Model to the Development of New Treatment Strategies for Parkinson's Disease. *Parkinsonism Relat. Disord.* **9**(3):131–137. [13]
- Jensen, K., J. Call, and M. Tomasello. 2007. Chimpanzees Are Rational Maximizers in an Ultimatum Game. *Science* **318**:108–109. [12]
- Jiang, Y. H., and M. D. Ehlers. 2013. Modeling Autism by Shank Gene Mutations in Mice. *Neuron* **78**(1):8–27. [4]
- Johnson, K. A., R. A. Sperling, C. M. Gidicsin, et al. 2013. Florbetapir (F18-AV-45) PET to Assess Amyloid Burden in Alzheimer's Disease Dementia, Mild Cognitive Impairment, and Normal Aging. *Alzheimers Dement.* **9**(Suppl. 5):S72–S83. [6]
- Jones, W., and A. Klin. 2013. Attention to Eyes Is Present but in Decline in 2-6-Month-Old Infants Later Diagnosed with Autism. *Nature* **504**(7480):427–431. [4]
- Jonsson, T., J. K. Atwal, S. Steinberg, et al. 2012. A Mutation in APP Protects against Alzheimer's Disease and Age-Related Cognitive Decline. *Nature* **488**(7409):96–99. [7]
- Jonsson, T., H. Stefansson, S. Steinberg, et al. 2013. Variant of TREM2 Associated with the Risk of Alzheimer's Disease. *N. Engl. J. Med.* **368**(2):107–116. [7]
- Joober, R., N. Schmitz, L. Annable, and P. Boksa. 2012. Publication Bias: What Are the Challenges and Can They Be Overcome? *J. Psychiatry Neurosci.* **37**(3):149–152. [2, 4]
- Ju, Y. E., B. P. Lucey, and D. M. Holtzman. 2014. Sleep and Alzheimer Disease Pathology: A Bidirectional Relationship. *Nat. Rev. Neurol.* **10**(2):115–119. [7]
- Julkunen, P., L. Säisänen, N. Danner, et al. 2009. Comparison of Navigated and Non-Navigated Transcranial Magnetic Stimulation for Motor Cortex Mapping, Motor Threshold and Motor Evoked Potentials. *NeuroImage* **44**:790–795. [10]
- Jurado, S., D. Goswami, Y. Zhang, et al. 2014. LTP Requires a Unique Postsynaptic Snare Fusion Machinery. *Neuron* **77**:542–558. [10]
- Kaale, A., M. W. Fagerland, E. W. Martinsen, and L. Smith. 2014. Preschool-Based Social Communication Treatment for Children with Autism: 12-Month Follow-up of a Randomized Trial. *J. Am. Acad. Child Adolesc. Psychiatry* **53**(2):188–198. [4]
- Kadoshima, T., H. Sakaguchi, T. Nakano, et al. 2013. Self-Organization of Axial Polarity, inside-out Layer Pattern, and Species-Specific Progenitor Dynamics in Human ES Cell-Derived Neocortex. *PNAS* **110**(50):20284–20289. [13]

- Kalthoff, D., C. Po, D. Wiedermann, and M. Hoehn. 2013. Reliability and Spatial Specificity of Rat Brain Sensorimotor Functional Connectivity Networks Are Superior under Sedation Compared with General Anesthesia. *NMR Biomed.* **26**:638–650. [9]
- Karimi, M., L. Tian, C. A. Brown, et al. 2013. Validation of Nigrostriatal Positron Emission Tomography Measures: Critical Limits. *Ann. Neurol.* **73**:390–396. [9, 10]
- Kawakubo, Y., S. Kamio, T. Nose, et al. 2007. Phonetic Mismatch Negativity Predicts Social Skills Acquisition in Schizophrenia. *Psychiatry Res.* **152**:261–265. [10]
- Kawakubo, Y., and K. Kasai. 2006. Support for an Association between Mismatch Negativity and Social Functioning in Schizophrenia. *Prog. Neuropsychopharmacol. Biol. Psychiatry* **30**:1367–1368. [10]
- Kawakubo, Y., K. Kasai, N. Kudo, et al. 2006. Phonetic Mismatch Negativity Predicts Verbal Memory Deficits in Schizophrenia. *Neuroreport* **17**:1043–1046. [10]
- Keeler, J. F., and T. W. Robbins. 2011. Translating Cognition from Animals to Humans. *Biochem. Pharmacol.* **81**:1356–1366. [12]
- Kelleher, R. J., III, and M. F. Bear. 2008. The Autistic Neuron: Troubled Translation? *Cell* **135**(3):401–406. [2]
- Kendell, R. E., J. E. Cooper, A. J. Gourlay, et al. 1971. Diagnostic Criteria of American and British Psychiatrists. *Arch. Gen. Psychiatry* **25**(2):123–130. [4]
- Kendler, K. S. 2006. Reflections on the Relationship between Psychiatric Genetics and Psychiatric Nosology. *Am. J. Psychiatry* **163**(7):1138–1146. [3]
- . 2013. What Psychiatric Genetics Has Taught Us About the Nature of Psychiatric Illness and What Is Left to Learn. *Mol. Psychiatry* **18**:1058–1066. [8]
- Kettleborough, R. N., E. M. Busch-Nentwich, S. A. Harvey, et al. 2013. A Systematic Genome-Wide Analysis of Zebrafish Protein-Coding Gene Function. *Nature* **496**:494–497. [8]
- Kim, E. J., G. D. Rabinovici, W. W. Seeley, et al. 2007. Patterns of MRI Atrophy in Tau Positive and Ubiquitin Positive Frontotemporal Lobar Degeneration. *J. Neurol. Neurosurg. Psychiatry* **78**:1375–1378. [9]
- Kim, J., J. M. Basak, and D. M. Holtzman. 2009. The Role of Apolipoprotein E in Alzheimer's Disease. *Neuron* **63**(3):287–303. [7]
- Kim, J., A. E. Eltorai, H. Jiang, et al. 2012. Anti-apoE Immunotherapy Inhibits Amyloid Accumulation in a Transgenic Mouse Model of A β Amyloidosis. *J. Exp. Med.* **209**(12):2149–2156. [7]
- Kim, J., H. Jiang, S. Park, et al. 2011. Haploinsufficiency of Human APOE Reduces Amyloid Deposition in a Mouse Model of Amyloid-Beta Amyloidosis. *J. Neurosci.* **31**(49):18007–18012. [7]
- Kim, Y. S., and M. W. State. 2014. Recent Challenges to the Psychiatric Diagnostic Nosology: A Focus on the Genetics and Genomics of Neurodevelopmental Disorders. *Int. J. Epidemiol.* **43**(2):465–475. [2]
- Kirov, G., A. J. Pocklington, P. Holmans, et al. 2012. *De Novo* CNV Analysis Implicates Specific Abnormalities of Postsynaptic Signalling Complexes in the Pathogenesis of Schizophrenia. *Mol. Psychiatry* **17**(2):142–153. [3, 4]
- Kirov, G., E. Rees, J. T. Walters, et al. 2014. The Penetrance of Copy Number Variations for Schizophrenia and Developmental Delay. *Biol. Psychiatry* **75**(5):378–385. [3, 13]
- Kirov, G., D. Rujescu, A. Ingason, et al. 2009. Neurexin 1 (NRXN1) Deletions in Schizophrenia. *Schizophr. Bull.* **35**(5):851–854. [3]
- Klapoetke, N. C., Y. Murata, S. S. Kim, et al. 2014. Independent Optical Excitation of Distinct Neural Populations. *Nat. Methods* **11**(3):338–346. [8, 10]

- Klei, L., S. J. Sanders, M. T. Murtha, et al. 2012. Common Genetic Variants, Acting Additively, Are a Major Source of Risk for Autism. *Mol. Autism* **3**(1):9. [2]
- Kleim, J. A., S. Chan, E. Pringle, et al. 2006. BDNF Val66met Polymorphism Is Associated with Modified Experience-Dependent Plasticity in Human Motor Cortex. *Nat. Neurosci.* **9**:735–737. [10]
- Klumpp, H., D. A. Fitzgerald, and K. L. Phan. 2013. Neural Predictors and Mechanisms of Cognitive Behavioral Therapy on Threat Processing in Social Anxiety Disorder. *Prog. Neuropsychopharmacol. Biol. Psychiatry* **45**:83–91. [10]
- Klunk, W. E., H. Engler, A. Nordberg, et al. 2004. Imaging Brain Amyloid in Alzheimer's Disease with Pittsburgh Compound-B. *Ann. Neurol.* **55**(3):306–319. [7]
- Kneeland, R. E., and S. H. Fatemi. 2013. Viral Infection, Inflammation and Schizophrenia. *Prog. Neuropsychopharmacol. Biol. Psychiatry* **42**:35–48. [13]
- Knox, A., A. Schneider, F. Abucayan, et al. 2012. Feasibility, Reliability, and Clinical Validity of the Test of Attentional Performance for Children (KiTAP) in Fragile X Syndrome (FXS). *J. Neurodev. Disord.* **4**:2. [10]
- Koga, H., M. Martinez-Vicente, E. Arias, et al. 2011. Constitutive Upregulation of Chaperone-Mediated Autophagy in Huntington's Disease. *J. Neurosci.* **31**(50):18492–18505. [5]
- Koldamova, R., N. F. Fitz, and I. Lefterov. 2010. The Role of ATP-Binding Cassette Transporter A1 in Alzheimer's Disease and Neurodegeneration. *Biochim. Biophys. Acta* **1801**(8):824–830. [7]
- Komatsu, M., S. Waguri, T. Chiba, et al. 2006. Loss of Autophagy in the Central Nervous System Causes Neurodegeneration in Mice. *Nature* **441**(7095):880–884. [5]
- Kong, A., M. L. Frigge, G. Masson, et al. 2012. Rate of *de Novo* Mutations and the Importance of Father's Age to Disease Risk. *Nature* **488**(7412):471–475. [2]
- Kordower, J. H., C. W. Olanow, H. B. Dodiya, et al. 2013. Disease Duration and the Integrity of the Nigrostriatal System in Parkinson's Disease. *Brain* **136**:2419–2431. [10]
- Krabbe, G., A. Halle, V. Matyash, et al. 2013. Functional Impairment of Microglia Coincides with Beta-Amyloid Deposition in Mice with Alzheimer-Like Pathology. *PLoS One* **8**(4):e60921. [7]
- Kravitz, A. V., B. S. Freeze, P. R. Parker, et al. 2010. Regulation of Parkinsonian Motor Behaviours by Optogenetic Control of Basal Ganglia Circuitry. *Nature* **466**:622–626. [9, 10]
- Krezowski, J., D. Knudson, C. Ebeling, et al. 2004. Identification of Loci Determining Susceptibility to the Lethal Effects of Amyloid Precursor Protein Transgene Overexpression. *Hum. Mol. Genet.* **13**(18):1989–1997. [6]
- LaFerla, F. M., and K. N. Green. 2012. Animal Models of Alzheimer Disease. *Cold Spring Harb. Perspect. Med.* **2**(11) [13]
- Lambert, J. C., C. A. Ibrahim-Verbaas, D. Harold, et al. 2013. Meta-Analysis of 74,046 Individuals Identifies 11 New Susceptibility Loci for Alzheimer's Disease. *Nat. Genet.* **45**:1452–1458. [1, 14]
- Lancaster, M. A., M. Renner, C. A. Martin, et al. 2013. Cerebral Organoids Model Human Brain Development and Microcephaly. *Nature* **501**(7467):373–379. [8, 11, 13, 14]
- Lang, A. E., S. Gill, N. K. Patel, et al. 2006. Randomized Controlled Trial of Intraputamenal Glial Cell Line-Derived Neurotrophic Factor Infusion in Parkinson Disease. *Ann. Neurol.* **59**(3):459–466. [7]

- Lang, N., H. R. Siebner, D. Ernst, et al. 2004. Preconditioning with Transcranial Direct Current Stimulation Sensitizes the Motor Cortex to Rapid-Rate Transcranial Magnetic Stimulation and Controls the Direction of after-Effects. *Biol. Psychiatry* **56**:634–639. [10]
- Laumonier, F., F. Bonnet-Brilhault, M. Gomot, et al. 2004. X-Linked Mental Retardation and Autism Are Associated with a Mutation in the NLGN4 Gene, a Member of the Neuroligin Family. *Am. J. Hum. Genet.* **74**(3):552–557. [4]
- Lawrie, S. M., B. Olabi, J. Hall, and A. M. McIntosh. 2011. Do We Have Any Solid Evidence of Clinical Utility About the Pathophysiology of Schizophrenia? *World Psychiatry* **10**(1):19–31. [3, 10]
- Leblond, C. S., J. Heinrich, R. Delorme, et al. 2012. Genetic and Functional Analyses of SHANK2 Mutations Suggest a Multiple Hit Model of Autism Spectrum Disorders. *PLoS Genet.* **8**(2):e1002521. [2, 4]
- LeDoux, J. E. 2000. Emotion Circuits in the Brain. *Annu. Rev. Neurosci.* **23**(1):155–184. [12]
- LeDoux, J. E. 2014. Coming to Terms with Fear. *PNAS* **111**:2871–2878. [8]
- Lee, B. H., M. J. Lee, S. Park, et al. 2010. Enhancement of Proteasome Activity by a Small-Molecule Inhibitor of USP14. *Nat. Chem. Biol.* **467**(7312):179–184. [5]
- Lee, H.-J., E.-J. Bae, and S.-J. Lee. 2014. Extracellular [Alpha]-Synuclein: A Novel and Crucial Factor in Lewy Body Diseases. *Nat. Rev. Neurol.* **10**(2):92–98. [7]
- Lee, H.-M., P. M. Giguere, and B. L. Roth. 2013. DREADDs: Novel Tools for Drug Discovery and Development. *Drug Discov. Today* **19**:469–473. [10]
- Lee, K.-H., L. M. Williams, M. Breakspear, and E. Gordon. 2003. Synchronous Gamma Activity: A Review and Contribution to an Integrative Neuroscience Model of Schizophrenia. *Brain Res. Rev.* **41**:57–78. [10]
- Lee, S. H., T. R. DeCandia, S. Ripke, et al. 2012. Estimating the Proportion of Variation in Susceptibility to Schizophrenia Captured by Common SNPs. *Nat. Genet.* **44**(3):247–250. [3]
- Lemon, R. N. 2008. Descending Pathways in Motor Control. *Annu. Rev. Neurosci.* **31**:195–218. [13]
- Lenin, V. I. 1917/1990. *Что Делать* [What Is to Be Done?], translated by J. Fineberg and G. Hanna. London: Penguin Classics. [1]
- Leonhard, K., H. Beckmann, and C. H. Cahn, eds. 1999. *Classification of Endogenous Psychoses and Their Differentiated Etiology*. Heidelberg: Springer. [3]
- Liang, G., and Y. Zhang. 2013. Genetic and Epigenetic Variations in iPSCs: Potential Causes and Implications for Application. *Cell Stem Cell* **13**:149–159. [11]
- Lichtenstein, P., B. H. Yip, C. Björk, et al. 2009. Common Genetic Determinants of Schizophrenia and Bipolar Disorder in Swedish Families: A Population-Based Study. *Lancet* **373**(9659):234–239. [3]
- Light, G. A., and D. L. Braff. 2005. Stability of Mismatch Negativity Deficits and Their Relationship to Functional Impairments in Chronic Schizophrenia. *Am. J. Psychiatry* **162**:1741–1743. [10]
- Light, G. A., and R. Näätänen. 2013. Mismatch Negativity Is a Breakthrough Biomarker for Understanding and Treating Psychotic Disorders. *PNAS* **110**:15175–15176. [10]
- Lim, A. L., D. A. Taylor, and D. T. Malone. 2012. A Two-Hit Model: Behavioural Investigation of the Effect of Combined Neonatal MK-801 Administration and Isolation Rearing in the Rat. *J. Psychopharmacol.* **26**(9):1252–1264. [13]
- Lim, E. T., S. Raychaudhuri, S. J. Sanders, et al. 2013. Rare Complete Knockouts in Humans: Population Distribution and Significant Role in Autism Spectrum Disorders. *Neuron* **77**(2):235–242. [2]

- Lima, S. Q., and G. Miesenböck. 2005. Remote Control of Behavior through Genetically Targeted Photostimulation of Neurons. *Cell* **121**:141–152. [10]
- Lin, J. Y., M. Z. Lin, P. Steinbach, and R. Y. Tsien. 2009. Characterization of Engineered Channelrhodopsin Variants with Improved Properties and Kinetics. *Biophys. J.* **96**:1803–1814. [10]
- Ling, S. C., M. Polymenidou, and D. W. Cleveland. 2013. Converging Mechanisms in ALS and FTD: Disrupted RNA and Protein Homeostasis. *Neuron* **79**(3):416–438. [5, 6]
- Lipska, B. K., and D. R. Weinberger. 2000. To Model a Psychiatric Disorder in Animals: Schizophrenia as a Reality Test. *Neuropsychopharmacology* **23**(3):223–239. [13]
- Lista, S., F. G. Garaci, M. Ewers, et al. 2014. CSF Abeta1-42 Combined with Neuroimaging Biomarkers in the Early Detection, Diagnosis and Prediction of Alzheimer's Disease. *Alzheimers Dement.* **10**(3):381–392. [13]
- Liu, G. H., J. Qu, K. Suzuki, et al. 2012. Progressive Degeneration of Human Neural Stem Cells Caused by Pathogenic LRRK2. *Nature* **491**:603–607. [11]
- Liu, H., Y. Chen, Y. Niu, et al. 2014. TALEN-Mediated Gene Mutagenesis in Rhesus and Cynomolgus Monkeys. *Cell Stem Cell* **14**:323–328. [8]
- Lobb, C. J., A. K. Zaheer, Y. Smith, and D. Jaeger. 2013. *In Vivo* Electrophysiology of Nigral and Thalamic Neurons in Alpha-Synuclein-Overexpressing Mice Highlights Differences from Toxin-Based Models of Parkinsonism. *J. Neurophysiol.* **110**:2792–2805. [9]
- Luo, L., E. Callaway, and K. Svoboda. 2008. Genetic Dissection of Neural Circuits. *Neuron* **57**:634–660. [10]
- Lüscher, C., and R. C. Malenka. 2011. Drug-Evoked Synaptic Plasticity in Addiction: From Molecular Changes to Circuit Remodeling. *Neuron* **69**:650–663. [10]
- Lustig, C., R. Kozak, M. Sarter, J. W. Young, and T. W. Robbins. 2013. CNTRICS Final Animal Model Task Selection: Control of Attention. *Neurosci. Biobehav. Res.* **37**:2099–2110. [12]
- Ma, Y., S. Peng, P. G. Spetsieris, et al. 2012. Abnormal Metabolic Brain Networks in a Nonhuman Primate Model of Parkinsonism. *J. Cereb. Blood Flow Metab.* **32**:633–642. [9]
- Mackintosh, N. J. 1983. *Conditioning and Associative Learning*. Oxford: Oxford Univ. Press. [12]
- Mahley, R. W., and Y. Huang. 2012. Apolipoprotein E Sets the Stage: Response to Injury Triggers Neuropathology. *Neuron* **76**(5):871–885. [7]
- Malaspina, D., M. J. Owen, S. Heckers, et al. 2013. Schizoaffective Disorder in the DSM-5. *Schizophr. Res.* **150**(1):21–25. [3]
- Maldonado, T. A., R. E. Jones, and D. O. Norris. 2002. Intraneuronal Amyloid Precursor Protein (APP) and Appearance of Extracellular Beta-Amyloid Peptide (Abeta) in the Brain of Aging Kokanee Salmon. *J. Neurobiol.* **53**(1):11–20. [6]
- Malhotra, D., and J. Sebat. 2012. CNVs: Harbingers of a Rare Variant Revolution in Psychiatric Genetics. *Cell* **148**(6):1223–1241. [3]
- Mali, P., K. M. Esvelt, and G. M. Church. 2013a. Cas9 as a Versatile Tool for Engineering Biology. *Nat. Methods* **19**:957–963. [8]
- Mali, P., L. Yang, K. M. Esvelt, et al. 2013b. RNA-Guided Human Genome Engineering via Cas9. *Science* **339**:823–826. [8]
- Manabe, T., D. J. Wyllie, D. J. Perkel, and R. A. Nicoll. 1993. Modulation of Synaptic Transmission and Long-Term Potentiation: Effects on Paired Pulse Facilitation and EPSC Variance in the CA1 Region of the Hippocampus. *J. Neurophysiol.* **70**:1451–1459. [10]

- Mandelkow, E. M., and E. Mandelkow. 2012. Biochemistry and Cell Biology of Tau Protein in Neurofibrillary Degeneration. *Cold Spring Harb. Perspect. Med.* **2(7)**:a006247. [7]
- Manly, J. J. 2008. Critical Issues in Cultural Neuropsychology: Profit from Diversity. *Neuropsychol. Rev.* **18(3)**:179–183. [2]
- Mantini, D., A. Gerits, K. Nelissen, et al. 2011. Default Mode of Brain Function in Monkeys. *J. Neurosci.* **31**:12954–12962. [9]
- Marchetto, M. C., C. Carroumeu, A. Acab, et al. 2010. A Model for Neural Development and Treatment of Rett Syndrome Using Human Induced Pluripotent Stem Cells. *Cell* **143**:527–539. [11]
- Marie, H., and R. C. Malenka. 2006. Acute *in Vivo* Expression of Recombinant Proteins in Rat Brain Using Sindbis Virus. In: *The Dynamic Synapse: Molecular Methods in Ionotropic Receptor Biology*, ed. J. T. Kittler and S. J. Moss. Boca Raton: CRC Press. [10]
- Marshall, M., and J. Rathbone. 2011. Early Intervention for Psychosis. *Cochrane Database Syst. Rev.* **6**:CD004718. [4]
- Martin-Ordas, G., D. Haun, and J. Call. 2010. Keeping Track of Time: Evidence for Episodic-Like Memory in Great Apes. *Anim. Cogn.* **13**:331–340. [12]
- Maruyama, M., H. Shimada, T. Suhara, et al. 2013. Imaging of Tau Pathology in a Tauopathy Mouse Model and in Alzheimer Patients Compared to Normal Controls. *Neuron* **79(6)**:1094–1108. [7]
- Masliah, E., E. Rockenstein, I. Veinbergs, et al. 2001. Beta-Amyloid Peptides Enhance Alpha-Synuclein Accumulation and Neuronal Deficits in a Transgenic Mouse Model Linking Alzheimer's Disease and Parkinson's Disease. *PNAS* **98(21)**:12245–12250. [7]
- Maxwell, C. R., Y. Liang, B. D. Weightman, et al. 2004. Effects of Chronic Olanzapine and Haloperidol Differ on the Mouse N1 Auditory Evoked Potential. *Neuropsychopharmacology* **29**:739–746. [10]
- Mazur, J. E., and R. J. Herrnstein. 1988. On the Functions Relating Delay, Reinforcer Value, and Behavior. *Behav. Brain Sci.* **11**:690–691. [12]
- McCarroll, S. A., G. Feng, and S. E. Hyman. 2014. Genome-Scale Neurogenetics: Methodology and Meaning. *Nat. Neurosci.* **17(6)**:756–763. [2, 8]
- McCarroll, S. A., and S. E. Hyman. 2013. Progress in Genetics of Polygenic Brain Disorders: Significant New Challenges for Neurobiology. *Neuron* **80**:578–587. [8, 14]
- McClintock, S. M., C. Freitas, L. Oberman, S. H. Lisanby, and A. Pascual-Leone. 2011. Transcranial Magnetic Stimulation: A Neuroscientific Probe of Cortical Function in Schizophrenia. *Biol. Psychiatry* **70(1)**:19–27. [13]
- McClure, S. M., D. I. Laibson, G. Loewenstein, and J. D. Cohen. 2004. Separate Neural Systems Value Immediate and Delayed Monetary Rewards. *Science* **306**:503–507. [12]
- McConnell, E. R., M. A. McClain, J. Ross, W. R. Lefew, and T. J. Shafer. 2012. Evaluation of Multi-Well Microelectrode Arrays for Neurotoxicity Screening Using a Chemical Training Set. *Neurotoxicology* **33**:1048–1057. [8]
- McFarland, H. F., F. Barkhof, J. Antel, and D. H. Miller. 2002. The Role of MRI as a Surrogate Outcome Measure in Multiple Sclerosis. *Mult. Scler.* **8(1)**:40–51. [6]
- McGaugh, J. L., and B. Roozendaal. 2008. Drug Enhancement of Memory Consolidation: Historical Perspective and Neurobiological Implications. *Psychopharmacology* **202**:3–14. [12]

- McGoldrick, P., P. I. Joyce, E. M. Fisher, and L. Greensmith. 2013. Rodent Models of Amyotrophic Lateral Sclerosis. *Biochim. Biophys. Acta* **1832**(9):1421–1436. [6]
- McKhann, G. M., D. S. Knopman, H. Chertkow, et al. 2011. The Diagnosis of Dementia Due to Alzheimer's Disease: Recommendations from the National Institute on Aging-Alzheimer's Association Workgroups on Diagnostic Guidelines for Alzheimer's Disease. *Alzheimers Dement.* **7**(3):263–269. [6]
- McTeague, L. M., and P. J. Lang. 2012. The Anxiety Spectrum and the Reflex Physiology of Defense: From Circumscribed Fear to Broad Distress. *Depress. Anxiety* **29**(4):264–281. [4]
- Medland, S. E., N. Jahanshad, B. M. Neale, and P. M. Thompson. 2014. Whole-Genome Analyses of Whole-Brain Data: Working within an Expanded Search Space. *Nat. Neurosci.* **17**(6):791–800. [2]
- Mehta, D., T. Klengel, K. N. Conneely, et al. 2013. Childhood Maltreatment Is Associated with Distinct Genomic and Epigenetic Profiles in Posttraumatic Stress Disorder. *PNAS* **110**(20):8302–8307. [4]
- Mendell, J. T., and E. N. Olson. 2012. Micrnas in Stress Signaling and Human Disease. *Cell* **148**(6):1172–1187. [7]
- Merkle, F. T., and K. Eggan. 2013. Modeling Human Disease with Pluripotent Stem Cells: From Genome Association to Function. *Cell Stem Cell* **12**:656–668. [11]
- Meyer-Luehmann, M., T. L. Spiess-Jones, C. Prada, et al. 2008. Rapid Appearance and Local Toxicity of Amyloid-Beta Plaques in a Mouse Model of Alzheimer's Disease. *Nature* **451**(7179):720–724. [7]
- Michalon, A., A. Bruns, C. Risterucci, et al. 2014. Chronic Metabotropic Glutamate Receptor 5 Inhibition Corrects Local Alterations of Brain Activity and Improves Cognitive Performance in Fragile X Mice. *Biol. Psychiatry* **75**(3):189–197. [13]
- Michie, P. T. 2001. What Has MMN Revealed About the Auditory System in Schizophrenia? *Int. J. Psychophysiol.* **42**:177–194. [10]
- Michie, P. T., T. W. Budd, J. Todd, et al. 2000. Duration and Frequency Mismatch Negativity in Schizophrenia. *Clin. Neurophysiol.* **111**:1054–1065. [10]
- Miller, C. T., K. Mandel, and X. Wang. 2010. The Communicative Content of the Common Marmoset Phee Call During Antiphonal Calling. *Am. J. Primatol.* **72**:974–980. [8]
- Miller, J. D., Y. M. Ganat, S. Kishinevsky, et al. 2013a. Human iPSC-Based Modeling of Late-Onset Disease via Progerin-Induced Aging. *Cell Stem Cell* **13**:691–705. [11, 13]
- Miller, T. M., A. Pestronk, W. David, et al. 2013b. An Antisense Oligonucleotide against SOD1 Delivered Intrathecally for Patients with SOD1 Familial Amyotrophic Lateral Sclerosis: A Phase 1, Randomised, First-in-Man Study. *Lancet Neurol.* **12**(5):435–442. [7]
- Milton, A. L., and B. J. Everitt. 2012. The Psychological and Neurochemical Mechanisms of Drug Memory Consolidation: Implications for the Treatment of Addiction. *Eur. J. Neurosci.* **31**:2308–2319. [12]
- Ming, G. L., O. Brustle, A. Muotri, et al. 2011. Cellular Reprogramming: Recent Advances in Modeling Neurological Diseases. *J. Neurosci.* **31**(45):16070–16075. [13]
- Mingozzi, F., and K. A. High. 2011. Therapeutic *in Vivo* Gene Transfer for Genetic Disease Using AAV: Progress and Challenges. *Nat. Rev. Genet.* **12**:341–355. [10]
- Mink, J. W. 1996. The Basal Ganglia: Focused Selection and Inhibition of Competing Motor Programs. *Prog. Neurobiol.* **50**:381–425. [9]

- Miocinovic, S., S. Somayajula, S. Chitnis, and J. L. Vitek. 2013. History, Applications, and Mechanisms of Deep Brain Stimulation. *JAMA Neurol.* **70**:163–171. [9]
- Mitsui, K., Y. Tokuzawa, H. Itoh, et al. 2003. The Homeoprotein Nanog Is Required for Maintenance of Pluripotency in Mouse Epiblast and ES Cells. *Cell* **113**(5):631–642. [13]
- Moghaddam, B. 2013. A Mechanistic Approach to Preventing Schizophrenia in At-Risk Individuals. *Neuron* **78**(1):1–3. [13]
- Moore, H., J. D. Jentsch, M. Ghajarnia, M. A. Geyer, and A. A. Grace. 2006. A Neurobehavioral Systems Analysis of Adult Rats Exposed to Methylazoxymethanol Acetate on E17: Implications for the Neuropathology of Schizophrenia. *Biol. Psychiatry* **60**(3):253–264. [13]
- Moreno-De-Luca, A., S. M. Myers, T. D. Challman, et al. 2013. Developmental Brain Dysfunction: Revival and Expansion of Old Concepts Based on New Genetic Evidence. *Lancet Neurol.* **12**(4):406–414. [2, 4]
- Morfini, G. A., M. Burns, L. I. Binder, et al. 2009. Axonal Transport Defects in Neurodegenerative Diseases. *J. Neurosci.* **29**(41):12776–12786. [5]
- Morris, K. V., and J. S. Mattick. 2014. The Rise of Regulatory RNA. *Nat. Rev. Genet.* **15**(6):423–437. [10]
- Morris, R. G. M., P. Garrud, J. N. P. Rawlins, and J. O’Keefe. 1982. Place Navigation Impaired in Rats with Hippocampal Lesions. *Nature* **297**:681–683. [12]
- Morrow, E. M., S. Y. Yoo, S. W. Flavell, et al. 2008. Identifying Autism Loci and Genes by Tracing Recent Shared Ancestry. *Science* **321**(5886):218–223. [2]
- Moskvina, V., N. Craddock, P. Holmans, et al. 2009. Gene-Wide Analyses of Genome-Wide Association Data Sets: Evidence for Multiple Common Risk Alleles for Schizophrenia and Bipolar Disorder and for Overlap in Genetic Risk. *Mol. Psychiatry* **14**(3):252–260. [3]
- Mottron, L. 2011. Changing Perceptions: The Power of Autism. *Nature* **479**(7371):33–35. [2]
- Moulder, K. L., B. J. Snider, S. L. Mills, et al. 2013. Dominantly Inherited Alzheimer Network: Facilitating Research and Clinical Trials. *Alzheimers Res. Ther.* **5**(5):48. [7]
- Moussavi, S., S. Chatterji, E. Verdes, et al. 2007. Depression, Chronic Diseases, and Decrements in Health: Results from the World Health Surveys. *Lancet* **370**:851–858. [1]
- Moy, S. S., J. J. Nadler, A. Perez, et al. 2004. Sociability and Preference for Social Novelty in Five Inbred Strains: An Approach to Assess Autistic-Like Behavior in Mice. *Genes Brain Behav.* **3**:287–302. [12]
- Murphy, F. C., B. J. Sahakian, J. S. Rubinsztein, et al. 1999. Emotional Bias and Inhibitory Control Processes in Mania and Depression. *Psychol. Med.* **29**:1307–1321. [12]
- Murray, C. J., T. Vos, R. Lozano, et al. 2012. Disability-Adjusted Life Years (Dalys) for 291 Diseases and Injuries in 21 Regions, 1990–2010: A Systematic Analysis for the Global Burden of Disease Study 2010. *Lancet* **380**:2163–2196. [1]
- Murray, E. A., T. J. Bussey, and L. M. Saksida. 2007. Visual Perception and Memory: A New View of Medial Temporal Lobe Function in Primates and Rodents. *Annu. Rev. Neurosci.* **30**:99–122. [12]
- Murray, R. M., and S. W. Lewis. 1987. Is Schizophrenia a Neurodevelopmental Disorder? *Br. Med. J. (Clin. Res. Ed.)* **295**(6600):681–682. [3, 13]

- Musiek, E. S., and D. M. Holtzman. 2012. Origins of Alzheimer's Disease: Reconciling Cerebrospinal Fluid Biomarker and Neuropathology Data Regarding the Temporal Sequence of Amyloid-Beta and Tau Involvement. *Curr. Opin. Neurobiol.* **25(6)**:715–720. [7]
- Näätänen, R. 2008. Mismatch Negativity (MMN) as an Index of Central Auditory System Plasticity. *Int. J. Audiol.* **47(Suppl 2)**:S16–20. [10]
- Näätänen, R., and S. Kähkönen. 2009. Central Auditory Dysfunction in Schizophrenia as Revealed by the Mismatch Negativity (MMN) and Its Magnetic Equivalent Mmm: A Review. *Int. J. Neuropsychopharmacol.* **12**:125–135. [10]
- Nader, K., and O. Hardt. 2009. A Single Standard for Memory: The Case for Reconsolidation. *Nat. Rev. Neurosci.* **10(3)**:224–234. [12]
- Nader, K., G. E. Schafe, and J. E. L. Doux. 2000. Fear Memories Require Protein Synthesis in the Amygdala for Reconsolidation after Retrieval. *Nature* **406**:722–726. [12]
- Nagai, M., D. B. Re, T. Nagata, et al. 2007. Astrocytes Expressing ALS-Linked Mutated SOD1 Release Factors Selectively Toxic to Motor Neurons. *Nat. Neurosci.* **10**:615–622. [11]
- Nagai, T., M. Tada, K. Kirihara, et al. 2013. Mismatch Negativity as a “Translatable” Brain Marker toward Early Intervention for Psychosis: A Review. *Front. Psychiatry* **4**:115. [10]
- Naj, A. C., G. Jun, G. W. Beecham, et al. 2011. Common Variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 Are Associated with Late-Onset Alzheimer's Disease. *Nat. Genet.* **43(5)**:436–441. [7]
- Nakano, T., S. Ando, N. Takata, et al. 2012. Self-Formation of Optic Cups and Storable Stratified Neural Retina from Human ESCs. *Cell Stem Cell* **10(6)**:771–785. [13]
- Neale, B. M., Y. Kou, L. Liu, et al. 2012. Patterns and Rates of Exonic *de Novo* Mutations in Autism Spectrum Disorders. *Nature* **485(7397)**:242–245. [2]
- Nelson, E. E., and J. T. Winslow. 2009. Non-Human Primates: Model Animals for Developmental Psychopathology. *Neuropsychopharmacology* **34(1)**:90–105. [13]
- Nestler, E. J., E. Gould, H. Manji, et al. 2002. Preclinical Models: Status of Basic Research in Depression. *Biol. Psychiatry* **52**:503–528. [12]
- Neve, R. L., K. A. Neve, E. J. Nestler, and W. A. Carlezon. 2005. Use of Herpes Virus Amplicon Vectors to Study Brain Disorders. *Biotechniques* **39**:381–391. [10]
- Nguyen, H. N., B. Byers, B. Cord, et al. 2011. LRRK2 Mutant iPSC-Derived DA Neurons Demonstrate Increased Susceptibility to Oxidative Stress. *Cell Stem Cell* **8**:267–280. [11]
- Nielsen, E. B., M. Lyon, and G. Ellison. 1983. Apparent Hallucinations in Monkeys During around-the Clock Amphetamine for Seven to Fourteen Days: Possible Relevance to Amphetamine Psychosis. *J. Nerv. Ment. Disord.* **171(4)**:222–233. [12]
- Niewoehner, J., B. Bohrmann, L. Collin, et al. 2014. Increased Brain Penetration and Potency of a Therapeutic Antibody Using a Monovalent Molecular Shuttle. *Neuron* **81(1)**:49–60. [7]
- Nishida, Y., S. Arakawa, K. Fujitani, et al. 2009. Discovery of Atg5/Atg7-Independent Alternative Macroautophagy. *Nat. Chem. Biol.* **461(7264)**:654–658. [5]
- Nithianantharajah, J., N. H. Komiyama, A. McKechnie, et al. 2013. Synaptic Scaffold Evolution Generated Components of Vertebrate Cognitive Complexity. *Nat. Neurosci.* **16**:16–24. [12]
- Nitsche, M. A., F. Müller-Dahlhaus, W. Paulus, and U. Ziemann. 2012. The Pharmacology of Neuroplasticity Induced by Non-Invasive Brain Stimulation: Building Models for the Clinical Use of CNS Active Drugs. *J. Physiol.* **590**:4641–4662. [10]

- Nitsche, M. A., A. Roth, M.-F. Kuo, et al. 2007. Timing-Dependent Modulation of Associative Plasticity by General Network Excitability in the Human Motor Cortex. *J. Neurosci.* **27**:3807–3812. [10]
- Niu, Y., B. Shen, Y. Cui, et al. 2014. Generation of Gene-Modified Cynomolgus Monkey via Cas9/RNA-Mediated Gene Targeting in One-Cell Embryos. *Cell* **156**(4):836–843. [6, 8, 13]
- Novarino, G., P. El-Fishawy, H. Kayserili, et al. 2012. Mutations in BCKD-Kinase Lead to a Potentially Treatable Form of Autism with Epilepsy. *Science* **338**(6105):394–397. [2]
- Obiany, O., and K. Ye. 2013. Novel Small Molecule Activators of the Trk Family of Receptor Tyrosine Kinases. *Biochim. Biophys. Acta* **1834**(10):2213–2218. [7]
- O'Donovan, M. C., N. Craddock, N. Norton, et al. 2008. Identification of Loci Associated with Schizophrenia by Genome-Wide Association and Follow-Up. *Nat. Genet.* **40**(9):1053–1055. [3]
- Okano, H., K. Hikishima, A. Iriki, and E. Sasaki. 2012. The Common Marmoset as a Novel Animal Model System for Biomedical and Neuroscience Research Applications. *Semin. Fetal Neonatal Med.* **17**:336–340. [8]
- Olanow, C. W., O. Rascol, R. Hauser, et al. 2009. A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease. *N. Engl. J. Med.* **361**(13):1268–1278. [6]
- Olton, D. S., and B. C. Paras. 1979. Spatial Memory and Hippocampal Function. *Neuropsychologia* **17**:669–682. [12]
- Orenstein, S. J., S. H. Kuo, I. Tasset, et al. 2013. Interplay of LRRK2 with Chaperone-Mediated Autophagy. *Nat. Neurosci.* **16**(4):394–406. [5]
- O'Roak, B. J., P. Deriziotis, C. Lee, et al. 2011. Exome Sequencing in Sporadic Autism Spectrum Disorders Identifies Severe *de Novo* Mutations. *Nat. Genet.* **43**(6):585–589. [2]
- O'Roak, B. J., L. Vives, W. Fu, et al. 2012a. Multiplex Targeted Sequencing Identifies Recurrently Mutated Genes in Autism Spectrum Disorders. *Science* **338**(6114):1619–1622. [2]
- O'Roak, B. J., L. Vives, S. Girirajan, et al. 2012b. Sporadic Autism Exomes Reveal a Highly Interconnected Protein Network of *de Novo* Mutations. *Nature* **485**(7397):246–250. [2]
- Ostergard, T., and J. P. Miller. 2014. Deep Brain Stimulation: New Directions. *J. Neurosurg. Sci.* **58**(4):191–198. [14]
- Oswal, A., P. Brown, and V. Litvak. 2013. Synchronized Neural Oscillations and the Pathophysiology of Parkinson's Disease. *Curr. Opin. Neurol.* **26**:662–670. [9]
- Owen, M. J. 2011. Is There a Schizophrenia to Diagnose? *World Psychiatry* **10**(1):34–35. [3]
- . 2012a. Implications of Genetic Findings for Understanding Schizophrenia. *Schizophr. Bull.* **38**:904–907. [3, 8]
- . 2012b. Intellectual Disability and Major Psychiatric Disorders: A Continuum of Neurodevelopmental Causality. *Br. J. Psychiatry* **200**:268–269. [3]
- Owen, M. J., M. C. O'Donovan, A. Thapar, and N. Craddock. 2011. Neurodevelopmental Hypothesis of Schizophrenia. *Br. J. Psychiatry* **198**(3):173–175. [3]
- Ozden, I., J. Wang, Y. Lu, et al. 2013. A Coaxial Optrode as Multifunction Write-Read Probe for Optogenetic Studies in Non-Human Primates. *J. Neurosci. Meth.*:142–154. [9]
- Ozerdema, A., B. Güntekind, M. I. Atagüne, and E. Başar. 2013. Brain Oscillations in Bipolar Disorder in Search of New Biomarkers. *Suppl. Clin. Neurophysiol.* **62**:207–221. [10]

- Pankevich, D. E., B. M. Altevogt, J. Dunlop, F. H. Gage, and S. E. Hyman. 2014. Improving and Accelerating Drug Development for Nervous System Disorders. *Neuron* **84**:546–553. [1, 14]
- Paoletti, P., C. Bellone, and Q. Zhou. 2013. NMDA Receptor Subunit Diversity: Impact on Receptor Properties, Synaptic Plasticity and Disease. *Nat. Rev. Neurosci.* **14**:383–400. [10]
- Parikshak, N. N., R. Luo, A. Zhang, et al. 2013. Integrative Functional Genomic Analyses Implicate Specific Molecular Pathways and Circuits in Autism. *Cell* **155**(5):1008–1021. [2, 10]
- Park, C., and A. M. Cuervo. 2013. Selective Autophagy: Talking with the UPS. *Cell Biochem. Biophys.* **67**(1):3–13. [5]
- Park, H. J., C. H. Kim, E. S. Park, et al. 2013. Increased GABA-a Receptor Binding and Reduced Connectivity at the Motor Cortex in Children with Hemiplegic Cerebral Palsy: A Multimodal Investigation Using 18F-Fluoroflumazenil PET, Immunohistochemistry, and MR Imaging. *J. Nucl. Med.* **54**:1263–1269. [9]
- Parkinson Study Group. 1989. Effect of Deprenyl on the Progression of Disability in Early Parkinson's Disease. *N. Engl. J. Med.* **321**(20):1364–1371. [6]
- . 1993. Effects of Tocopherol and Deprenyl on the Progression of Disability in Early Parkinson's Disease. *N. Engl. J. Med.* **328**(3):176–183. [6]
- Pasamanick, B., M. E. Rogers, and A. M. Lilienfeld. 1956. Pregnancy Experience and the Development of Behavior Disorders in Children. *Am. J. Psychiatry* **112**:613–618. [3]
- Paterson, N. E., and A. Markou. 2007. Animal Models and Treatments for Addiction and Depression Co-Morbidity. *Neurotox. Res.* **11**:1–32. [12]
- Patil, S. T., L. Zhang, F. Martenyi, et al. 2007. Activation of mGlu2/3 Receptors as a New Approach to Treat Schizophrenia: A Randomized Phase 2 Clinical Trial. *Nat. Med.* **13**(9):1102–1107. [13]
- Paul, B. D., J. I. Sbdio, R. Xu, et al. 2014. Cystathionine γ -Lyase Deficiency Mediates Neurodegeneration in Huntington's Disease. *Nature* **508**:96–100. [10]
- Paulsen, J. S., J. D. Long, C. A. Ross, et al. 2014. Prediction of Manifest Huntington's Disease with Clinical and Imaging Measures: A Prospective Observational Study. *Lancet Neurol.* **13**(12):1193–1201. [5]
- Peca, J., C. Feliciano, J. T. Ting, et al. 2011. Shank3 Mutant Mice Display Autistic-Like Behaviours and Striatal Dysfunction. *Nature* **472**(7344):437–442. [2, 4]
- Penn, D. C., and D. J. Povinelli. 2007. On the Lack of Evidence That Non-Human Animals Possess Anything Remotely Resembling a "Theory of Mind." *Philos. Trans. R. Soc. Lond.* **362**:731–744. [12]
- Perkins, D. O. 2006. Review: Longer Duration of Untreated Psychosis Is Associated with Worse Outcome in People with First Episode Psychosis. *Evid. Based Ment. Health* **9**(2):36. [4]
- Perou, R., R. H. Bitsko, S. J. Blumberg, et al. 2013. Mental Health Surveillance among Children: United States, 2005–2011. *MMWR Surveill. Summ.* **62**(Suppl 2):1–35. [2]
- Perrat, P. N., S. DasGupta, J. Wang, et al. 2013. Transposition-Driven Genomic Heterogeneity in the *Drosophila* Brain. *Science* **340**(6128):91–95. [5]
- Perry, D. C., and B. L. Miller. 2013. Frontotemporal Dementia. *Semin. Neurol.* **33**(4):336–341. [7]
- Petersen, R. C., R. G. Thomas, M. Grundman, et al. 2005. Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment. *N. Engl. J. Med.* **352**(23):2379–2388. [6]

- Pinto, D., A. T. Pagnamenta, L. Klei, et al. 2010. Functional Impact of Global Rare Copy Number Variation in Autism Spectrum Disorders. *Nature* **466(7304)**:368–372. [2]
- Poduri, A., G. D. Evrony, X. Cai, and C. A. Walsh. 2013. Somatic Mutation, Genomic Variation, and Neurological Disease. *Science* **341(6141)**:1237758. [2]
- Poline, J. B., J. L. Breeze, S. Ghosh, et al. 2012. Data Sharing in Neuroimaging Research. *Front. Neuroinform.* **6**:9. [2]
- Polymeropoulos, M. H. 2000. Genetics of Parkinson's Disease. *Ann. NY Acad. Sci.* **920**:28–32. [13]
- Pop, A. S., J. Levenga, C. E. de Esch, et al. 2014. Rescue of Dendritic Spine Phenotype in Fmr1 KO Mice with the mGluR5 Antagonist AFQ056/Mavoglurant. *Psychopharmacology* **231(6)**:1227–1235. [13]
- Posner, M. I., and S. E. Petersen. 1990. The Attention System of the Human Brain. *Annu. Rev. Neurosci.* **13**:25–42. [12]
- Posporelis, S., A. Sawa, G. S. Smith, et al. 2014. Promoting Careers in Academic Research to Psychiatry Residents. *Acad. Psychiatry* **38(2)**:185–190. [13]
- Pouladi, M. A., A. J. Morton, and M. R. Hayden. 2013. Choosing an Animal Model for the Study of Huntington's Disease. *Nat. Rev. Neurosci.* **14(10)**:708–721. [6]
- Pouladi, M. A., L. M. Stanek, Y. Xie, et al. 2012. Marked Differences in Neurochemistry and Aggregates Despite Similar Behavioural and Neuropathological Features of Huntington Disease in the Full-Length Bhdh and Yac128 Mice. *Hum. Mol. Genet.* **21**:2219–2232. [9]
- Preuss, T. M. 1995. Do Rats Have Prefrontal Cortex? The Rose-Woolsey-Akert Program Reconsidered. *J. Cogn. Neurosci.* **7**:1–24. [8]
- Pringle, A., M. Browning, P. J. Cowen, and C. J. Harmer. 2011. A Cognitive Neuropsychological Model of Antidepressant Drug Action. *Prog. Neuropsychopharmacol. Biol. Psychiatry* **35**:1586–1592. [12]
- Prinz, F., T. Schlange, and K. Asadullah. 2011a. Believe It or Not: How Much Can We Rely on Published Data on Potential Drug Targets? *Nat. Rev. Drug Discov.* **10(9)**:712. [6]
- Prinz, M., J. Priller, S. S. Sisodia, and R. M. Ransohoff. 2011b. Heterogeneity of CNS Myeloid Cells and Their Roles in Neurodegeneration. *Nat. Neurosci.* **14(10)**:1227–1235. [7]
- Purcell, S. M., J. L. Moran, M. Fromer, et al. 2014. A Polygenic Burden of Rare Disruptive Mutations in Schizophrenia. *Nature* **506(7487)**:185–190. [3, 4]
- Raby, C. R., D. M. Alexis, A. Dickinson, and N. S. Clayton. 2007. Planning for the Future by Western Scrub-Jays. *Nature* **445**:919–921. [10]
- Racette, B. A., L. Good, J. A. Antenor, et al. 2006. [18F]FDOPA PET as an Endophenotype for Parkinson's Disease Linkage Studies. *Am. J. Med. Genet. B Neuropsychiatr. Genet.* **141**:245–249. [9]
- Rafii, M. S., T. L. Baumann, R. A. Bakay, et al. 2014. A Phase I Study of Stereotactic Gene Delivery of AAV2-NGF for Alzheimer's Disease. *Alzheimers Dement.* [7]
- Ramaswami, M., J. P. Taylor, and R. Parker. 2013. Altered Ribostasis: RNA-Protein Granules in Degenerative Disorders. *Cell* **154(4)**:727–736. [5]
- Ramocki, M. B., and H. Y. Zoghbi. 2008. Failure of Neuronal Homeostasis Results in Common Neuropsychiatric Phenotypes. *Nature* **455(7215)**:912–918. [2]
- Ran, F. A., P. D. Hsu, J. Wright, et al. 2013. Genome Engineering Using the CRISPR-Cas9 System. *Nat. Protoc.* **8**:2281–2308. [10]
- Ravina, B., D. Eidelberg, J. E. Ahlskog, et al. 2005. The Role of Radiotracer Imaging in Parkinson Disease. *Neurology* **64**:208–215. [9]

- Reardon, S. 2014. NIH Rethinks Psychiatry Trials. *Nature* **507(7492)**:288. [4]
- Rees, E., J. T. Walters, L. Georgieva, et al. 2014. Analysis of Copy Number Variations at 15 Schizophrenia-Associated Loci. *Br. J. Psychiatry* **204(2)**:108–114. [3]
- Regier, D. A., W. E. Narrow, D. E. Clarke, et al. 2013. DSM-5 Field Trials in the United States and Canada, Part II: Test-Retest Reliability of Selected Categorical Diagnoses. *Am. J. Psychiatry* **170(1)**:59–70. [4]
- Reilly, M. T., G. J. Faulkner, J. Dubnau, I. Ponomarev, and F. H. Gage. 2013. The Role of Transposable Elements in Health and Diseases of the Central Nervous System. *J. Neurosci.* **33(45)**:17577–17586. [5]
- Reiman, E. M., J. B. Langbaum, A. S. Fleisher, et al. 2011. Alzheimer's Prevention Initiative: A Plan to Accelerate the Evaluation of Presymptomatic Treatments. *J. Alzheimer. Dis.* **26 (Suppl. 3)**:321–329. [6]
- Riley, B. E., S. J. Gardai, D. Emig-Agius, et al. 2014. Systems-Based Analyses of Brain Regions Functionally Impacted in Parkinson's Disease Reveals Underlying Causal Mechanisms. *PLoS One* **9(8)**:e102909. [14]
- Ripke, S., C. O'Dushlaine, K. Chambert, et al. 2013. Genome-Wide Association Analysis Identifies 13 New Risk Loci for Schizophrenia. *Nat. Genet.* **45(10, 13)**:1150–1159. [3, 4, 13]
- Rissling, A. J., S. Makeig, D. L. Braff, and G. A. Light. 2010. Neurophysiologic Markers of Abnormal Brain Activity in Schizophrenia. *Curr. Psychiatry Rep.* **12**:572–578. [10]
- Rissling, A. J., S.-H. Park, J. W. Young, et al. 2013. Demand and Modality of Directed Attention Modulate “Pre-Attentive” Sensory Processes in Schizophrenia Patients and Nonpsychiatric Controls. *Schizophr. Res.* **146**:326–335. [10]
- Robbins, T. W. 2002. The 5-Choice Serial Reaction Time Task: Behavioral Pharmacology and Functional Neurochemistry. *Psychopharmacology* **163**:362–380. [12]
- . 2014. The Neuropsychopharmacology of Attention. In: *The Handbook of Attention*, ed. K. Nobre and S. Kastner, pp. 509–541. Oxford: Oxford Univ. Press. [12]
- Robbins, T. W., and A. F. Arnsten. 2009. The Neuropsychopharmacology of Fronto-Executive Function: Monoaminergic Modulation. *Annu. Rev. Neurosci.* **32**:267–287. [13]
- Robins, E., and S. B. Guze. 1970. Establishment of Diagnostic Validity in Psychiatric Illness: Its Application to Schizophrenia. *Am. J. Psychiatry* **126**:983–987. [3]
- Robinson, E. S. J., D. M. Eagle, A. C. Mar, et al. 2008. Similar Effects of the Selective Noradrenaline Reuptake Inhibitor Atomoxetine on Three Distinct Forms of Impulsivity in the Rat. *Neuropsychopharmacology* **33**:1028–1037. [12]
- Robinson, R. G., K. L. Kubos, L. B. Starr, K. Rao, and T. R. Price. 1984. Mood Disorders in Stroke Patients. Importance of Location of Lesion. *Brain* **107 (Pt 1)**:81–93. [13]
- Rodriguez-Navarro, J. A., S. Kaushik, H. Koga, et al. 2012. Inhibitory Effect of Dietary Lipids on Chaperone-Mediated Autophag. *PNAS* **109(12)**:E705–714. [5]
- Romberg, C., M. P. Mattson, M. R. Mughal, T. J. Bussey, and L. M. Saksida. 2011. Impaired Attention in the 3xTgAD Mouse Model of Alzheimer's Disease: Rescue by Donepezil (Aricept). *J. Neurosci.* **31(9)**:3500–3507. [13]
- Rosen, R. F., A. S. Farberg, M. Gearing, et al. 2008. Tauopathy with Paired Helical Filaments in an Aged Chimpanzee. *J. Comp. Neurol.* **509(3)**:259–270. [6]
- Rosin, B., M. Slovik, R. Mitelman, et al. 2011. Closed-Loop Deep Brain Stimulation Is Superior in Ameliorating Parkinsonism. *Neuron* **72(2)**:370–384. [13]
- Ross, C. A., E. H. Aylward, E. J. Wild, et al. 2014. Huntington Disease: Natural History, Biomarkers and Prospects for Therapeutics. *Nat. Rev. Neurol.* **10(4)**:204–216. [13]

- Ross, R. M., N. A. McNair, S. L. Fairhall, et al. 2008. Induction of Orientation-Specific LTP-Like Changes in Human Visual Evoked Potentials by Rapid Sensory Stimulation. *Brain Res. Bull.* **76**:97–101. [10]
- Rossi, S., M. Hallett, P. M. Rossini, and A. Pascual-Leone. 2009. Safety, Ethical Considerations, and Application Guidelines for the Use of Transcranial Magnetic Stimulation in Clinical Practice and Research. *Clin. Neurophysiol.* **120**:2008–2039. [10]
- Rossini, P. M., S. Rossi, C. Babiloni, and J. Polich. 2007. Clinical Neurophysiology of Aging Brain: From Normal Aging to Neurodegeneration. *Prog. Neurobiol.* **83**:375–400. [9]
- Rosti, R. O., A. A. Sadek, K. K. Vaux, and J. G. Gleeson. 2014. The Genetic Landscape of Autism Spectrum Disorders. *Dev. Med. Child Neurol.* **56**:12–18. [8]
- Roth, G. S., J. A. Mattison, M. A. Ottinger, et al. 2004. Aging in Rhesus Monkeys: Relevance to Human Health Interventions. *Science* **305(5689)**:1423–1426. [13]
- Rothkegel, H., M. Sommer, and W. Paulus. 2010. Breaks During 5 Hz rTMS Are Essential for Facilitatory after Effects. *Clin. Neurophysiol.* **121**:426–430. [10]
- Rubin, L. L. 2008. Stem Cells and Drug Discovery: The Beginning of a New Era? *Cell* **132**:549–552. [11]
- Ruderfer, D. M., A. H. Fanous, S. Ripke, et al. 2013. Polygenic Dissection of Diagnosis and Clinical Dimensions of Bipolar Disorder and Schizophrenia. *Mol. Psychiatry* **19(9)**:1017–1024. [3]
- Rutter, M., J. Kim-Cohen, and B. Maughan. 2006. Continuities and Discontinuities in Psychopathology between Childhood and Adult Life. *J. Child Psychol. Psychiatry* **47(3-4)**: 276–295. [3]
- Ryan, S. D., N. Dolatabadi, S. F. Chan, et al. 2013. Isogenic Human iPSC Parkinson's Model Shows Nitrosative Stress-Induced Dysfunction in MEF2-PGC1alpha Transcription. *Cell* **155(6)**:1351–1364. [5]
- Sahakian, B. J., A. M. Owen, N. J. Morant, et al. 1993. Further Analysis of the Cognitive Effects of Tetrahydroaminoacridine (THA) in Alzheimer's Disease: Assessment of Attentional and Mnemonic Function Using CANTAB. *Psychopharmacology* **110**:395–401. [12, 13]
- Sahakian, K., and R. Jaenisch. 2009. Technical Challenges in Using Human Induced Pluripotent Stem Cells to Model Disease. *Cell Stem Cell* **5(6)**:584–595. [13]
- Salinas, S., G. Schiavo, and E. J. Kremer. 2010. A Hitchhiker's Guide to the Nervous System: The Complex Journey of Viruses and Toxins. *Nat. Rev. Microbiol.* **8**:645–655. [10]
- Salloway, S., R. Sperling, and H. R. Brashear. 2014a. Phase 3 Trials of Solanezumab and Bapineuzumab for Alzheimer's Disease. *N. Engl. J. Med.* **370(15)**:1460. [7]
- Salloway, S., R. Sperling, N. C. Fox, et al. 2014b. Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease. *N. Engl. J. Med.* **370(4)**:322–333. [6]
- Sanchez, P. E., L. Zhu, L. Verret, et al. 2012. Levetiracetam Suppresses Neuronal Network Dysfunction and Reverses Synaptic and Cognitive Deficits in an Alzheimer's Disease Model. *PNAS* **109(42)**:E2895–2903. [7]
- Sanders, S. J., A. G. Ercan-Sencicek, V. Hus, et al. 2011. Multiple Recurrent *de Novo* CNVs, Including Duplications of the 7q11.23 Williams Syndrome Region, Are Strongly Associated with Autism. *Neuron* **70(5)**:863–885. [2]
- Sanders, S. J., M. T. Murtha, A. R. Gupta, et al. 2012. *De Novo* Mutations Revealed by Whole-Exome Sequencing Are Strongly Associated with Autism. *Nature* **485(7397)**:237–241. [2]

- SantaCruz, K., J. Lewis, T. Spires, et al. 2005. Tau Suppression in a Neurodegenerative Mouse Model Improves Memory Function. *Science* **309(5733)**:476–481. [6]
- Sasai, Y. 2013. Next-Generation Regenerative Medicine: Organogenesis from Stem Cells in 3D Culture. *Cell Stem Cell* **12**:520–530. [11]
- Sasaki, E., H. Suemizu, A. Shimada, et al. 2009. Generation of Transgenic Non-Human Primates with Germline Transmission. *Nature* **459(7246)**:523–527. [6, 13]
- Sato, D., A. C. Lionel, C. S. Leblond, et al. 2012. Shank1 Deletions in Males with Autism Spectrum Disorder. *Am. J. Hum. Genet.* **90(5)**:879–887. [4]
- Schafer, D. P., E. K. Lehrman, A. G. Kautzman, et al. 2012. Microglia Sculpt Postnatal Neural Circuits in an Activity and Complement-Dependent Manner. *Neuron* **74(4)**:691–705. [7]
- Schiel, N., and L. Huber. 2006. Social Influences on the Development of Foraging Behavior in Free-Living Common Marmosets (*Callithrix jacchus*). *Am. J. Primatol.* **68**:1150–1160. [8]
- Schizophrenia Working Group of the Psychiatric Genomics Consortium. 2014. Biological Insights from 108 Schizophrenia-Associated Genetic Loci. *Nature* **511**:421–427. [1, 3, 10]
- Schmeisser, M. J., E. Ey, S. Wegener, et al. 2012. Autistic-Like Behaviours and Hyperactivity in Mice Lacking ProSAP1/Shank2. *Nature* **486(7402)**:256–260. [2, 4]
- Schmiedt, C., A. Brand, H. Hildebrandt, and C. Basar-Eroglu. 2005. Event-Related Theta Oscillations During Working Memory Tasks in Patients with Schizophrenia and Healthy Controls. *Cogn. Brain Res.* **25**:936–947. [10]
- Schneider, J. S., E. Y. Pioli, Y. Jianzhong, Q. Li, and E. Bezard. 2013. Levodopa Improves Motor Deficits but Can Further Disrupt Cognition in a Macaque Parkinson Model. *Mov. Disord.* **28**:663–667. [9]
- Schneider, J. S., G. Unguez, A. Yuwiler, S. C. Berg, and C. H. Markham. 1988. Deficits in Operant Behaviour in Monkeys Treated with N-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP). *Brain* **111(Pt 6)**:1265–1285. [9]
- Schrijvers, E. M., B. F. Verhaaren, P. J. Koudstaal, et al. 2012. Is Dementia Incidence Declining? Trends in Dementia Incidence since 1990 in the Rotterdam Study. *Neurology* **78(19)**:1456–1463. [7]
- Schultz, W., and A. Dickinson. 2000. Neuronal Coding of Prediction Errors. *Annu. Rev. Neurosci.* **23**:473–500. [12]
- Schwab, M. E. 2004. Nogo and Axon Regeneration. *Curr. Opin. Neurobiol.* **14(1)**:118–124. [13]
- Schwarz, S., L. Froelich, and A. Burns. 2012. Pharmacological Treatment of Dementia. *Curr. Opin. Psychiatry* **25(6)**:542–550. [13]
- Sekar, S., E. Jonckers, M. Verhoye, et al. 2013. Subchronic Memantine Induced Concurrent Functional Disconnectivity and Altered Ultra-Structural Tissue Integrity in the Rodent Brain: Revealed by Multimodal MRI. *Psychopharmacology* **227**:479–491. [9]
- Seminowicz, D. A., H. S. Mayberg, A. R. McIntosh, et al. 2004. Limbic-Frontal Circuitry in Major Depression: A Path Modeling Metanalysis. *NeuroImage* **22**:409–418. [10]
- Seok, J., H. S. Warren, A. G. Cuenca, et al. 2013. Inflammation and Host Response to Injury, Large Scale Collaborative Research Program. Genomic Responses in Mouse Models Poorly Mimic Human Inflammatory Diseases. *PNAS* **110**:3507–3512. [11]
- Serio, A., B. Bilican, S. J. Barmada, et al. 2013. Astrocyte Pathology and the Absence of Non-Cell Autonomy in an Induced Pluripotent Stem Cell Model of TDP-43 Proteinopathy. *PNAS* **110(12)**:4697–4702. [5]

- Shafi, M. M., M. B. Westover, M. D. Fox, and A. Pascual-Leone. 2012. Exploration and Modulation of Brain Network Interactions with Noninvasive Brain Stimulation in Combination with Neuroimaging. *Eur. J. Neurosci.* **35**(6):805–825. [13]
- Shao, K., R. Huang, J. Li, et al. 2010. Angiopep-2 Modified PE-PEG Based Polymeric Micelles for Amphotericin B Delivery Targeted to the Brain. *J. Control Release* **147**(1):118–126. [7]
- Sharma, K., S. Y. Choi, Y. Zhang, et al. 2013. High-Throughput Genetic Screen for Synaptogenic Factors: Identification of LRP6 as Critical for Excitatory Synapse Development. *Cell Rep.* **5**:1330–1341. [8]
- Shay, T., V. Jojic, O. Zuk, et al. 2013. Conservation and Divergence in the Transcriptional Programs of the Human and Mouse Immune Systems. *PNAS* **110**(8):2946–2951. [6]
- Shcheglovitov, A., O. Shcheglovitova, M. Yazawa, et al. 2013. SHANK3 and IGF1 Restore Synaptic Deficits in Neurons from 22q13 Deletion Syndrome Patients. *Nature* **503**(7475):267–271. [2, 4, 11]
- Sheline, Y. I., M. E. Raichle, A. Z. Snyder, et al. 2010. Amyloid Plaques Disrupt Resting State Default Mode Network Connectivity in Cognitively Normal Elderly. *Biol. Psychiatry* **67**:584–587. [9]
- Sidorov, M. S., B. D. Auerbach, and M. F. Bear. 2013. Fragile X Mental Retardation Protein and Synaptic Plasticity. *Mol. Brain* **6**:15. [10]
- Siebner, H. R., T. O. Bergmann, S. Bestmann, et al. 2009. Consensus Paper: Combining Transcranial Stimulation with Neuroimaging. *Brain Stimul.* **2**:58–80. [10]
- Siegel, M. S., and E. Y. Isacoff. 1997. A Genetically Encoded Optical Probe of Membrane Voltage. *Neuron* **19**:735–741. [10]
- Silverman, J. L., M. Yang, C. Lord, and J. N. Crawley. 2010. Behavioural Phenotyping Assays for Mouse Models of Autism. *Nat. Rev. Neurosci.* **11**(7):490–502. [2]
- Sliwkowski, M. X., and I. Mellman. 2013. Antibody Therapeutics in Cancer. *Science* **341**(6151):1192–1198. [13]
- Smith, S. M., C. F. Beckmann, J. Andersson, et al. 2013. Resting-State fMRI in the Human Connectome Project. *NeuroImage* **80**:144–168. [14]
- Solanto, M. V., H. Abikoff, E. Sonuga-Barke, et al. 2001. The Ecological Validity of Delay Aversion and Response Inhibition as Measures of Impulsivity in AD/HD: A Supplement to the NIMH Multimodal Treatment Study of AD/HD. *J. Abnorm. Child Psychol.* **29**(3):215–228. [12]
- Sowman, P. F., S. S. Dueholm, J. H. Rasmussen, and N. Mrachacz-Kersting. 2014. Induction of Plasticity in the Human Motor Cortex by Pairing an Auditory Stimulus with TMS. *Front. Hum. Neurosci.* **8**:398. [10]
- Spencer, B., R. A. Marr, R. Gindi, et al. 2011. Peripheral Delivery of a CNS Targeted, Metallo-Protease Reduces Abeta Toxicity in a Mouse Model of Alzheimer's Disease. *PLoS One* **6**(1):e16575. [7]
- Sperling, R. A., P. S. Aisen, L. A. Beckett, et al. 2011a. Toward Defining the Preclinical Stages of Alzheimer's Disease: Recommendations from the National Institute on Aging-Alzheimer's Association Workgroups on Diagnostic Guidelines for Alzheimer's Disease. *Alzheimers Dement.* **7**(3):280–292. [7]
- Sperling, R. A., C. R. Jack, Jr., and P. S. Aisen. 2011b. Testing the Right Target and Right Drug at the Right Stage. *Sci. Transl. Med.* **3**(111):111cm133. [6]
- Spiegel, R., M. Berres, A. R. Miserez, and A. U. Monsch. 2011. For Debate: Substituting Placebo Controls in Long-Term Alzheimer's Prevention Trials. *Alzheimers Res. Ther.* **3**(2):9. [6]

- Spooren, W., L. Lindemann, A. Ghosh, and L. Santarelli. 2012. Synapse Dysfunction in Autism: A Molecular Medicine Approach to Drug Discovery in Neurodevelopmental Disorders. *Trends Pharmacol. Sci.* **33(12)**:669–684. [2]
- Squire, L. R. 1992. Memory and the Hippocampus: A Synthesis from Findings with Rats, Monkeys, and Humans. *Psychol. Rev.* **99**:195–231. [12]
- Stein, T. D., V. E. Alvarez, and A. C. McKee. 2014. Chronic Traumatic Encephalopathy: A Spectrum of Neuropathological Changes Following Repetitive Brain Trauma in Athletes and Military Personnel. *Alzheimers Res. Ther.* **6(1)**:4. [7]
- Steinberg, E. E., J. R. Boivin, B. T. Saunders, et al. 2014. Positive Reinforcement Mediated by Midbrain Dopamine Neurons Requires D1 and D2 Receptor Activation in the Nucleus Accumbens. *PLoS One* **14(9)**:e94771. [14]
- Steinberg, J., and C. Webber. 2013. The Roles of FMRP-Regulated Genes in Autism Spectrum Disorder: Single- and Multiple-Hit Genetic Etiologies. *Am. J. Hum. Genet.* **93(5)**:825–839. [4]
- Stella, S. L., A. Vila, A. Y. Hung, et al. 2012. Association of Shank 1a Scaffolding Protein with Cone Photoreceptor Terminals in the Mammalian Retina. *PLoS One* **7**:e43463. [10]
- Stephan, A. H., D. V. Madison, J. M. Mateos, et al. 2013. A Dramatic Increase of C1q Protein in the CNS During Normal Aging. *J. Neurosci.* **33(33)**:13460–13474. [5]
- Stewart, A. M., O. Braubach, J. Spitsbergen, R. Gerlai, and A. V. Kalueff. 2014. Zebrafish Models for Translational Neuroscience Research: From Tank to Bedside. *Trends Neurosci.* **37**:264–278. [8]
- St. Johnston, D. 2002. The Art and Design of Genetic Screens: *Drosophila Melanogaster*. *Nat. Rev. Genet.* **3**:176–188. [8]
- Stoner, R., M. L. Chow, M. P. Boyle, et al. 2014. Patches of Disorganization in the Neocortex of Children with Autism. *N. Engl. J. Med.* **370(13)**:1209–1219. [2]
- St-Pierre, F., J. D. Marshall, Y. Yang, et al. 2014. High-Fidelity Optical Reporting of Neuronal Electrical Activity with an Ultrafast Fluorescent Voltage Sensor. *Nature Neurosci.* **17(6)**:884–889. [10]
- Strittmatter, W. J., and A. D. Roses. 1996. Apolipoprotein E and Alzheimer's Disease. *Annu. Rev. Neurosci.* **19**:53–77. [7]
- Stuart, S. A., P. Butler, M. Munafo, D. J. Nutt, and E. S. J. Robinson. 2013. A Translational Rodent Assay of Affective Biases in Depression and Antidepressant Therapy. *Neuropsychopharmacology* **38**:1625–1635. [12]
- Sullivan, P. F., M. J. Daly, and M. C. O'Donovan. 2012. Genetic Architectures of Psychiatric Disorders: The Emerging Picture and Its Implications. *Nat. Rev. Genet.* **13(8)**:537–551. [3]
- Sullivan, P. F., K. S. Kendler, and M. C. Neale. 2003. Schizophrenia as a Complex Trait: Evidence from a Meta-Analysis of Twin Studies. *Arch. Gen. Psychiatry* **60(12)**:1187–1192. [13]
- Swainson, R., J. R. Hodges, C. J. Galton, et al. 2001. Early Detection and Differential Diagnosis of Alzheimer's Disease and Depression with Neuropsychological Tasks. *Dement. Geri. Cogn. Dis.* **12**:265–280. [12]
- Szatmari, P., A. D. Paterson, L. Zwaigenbaum, et al. 2007. Mapping Autism Risk Loci Using Genetic Linkage and Chromosomal Rearrangements. *Nat. Genet.* **39(3)**:319–328. [2]
- Tabbal, S. D., L. Tian, M. Karimi, et al. 2012. Low Nigrostriatal Reserve for Motor Parkinsonism in Nonhuman Primates. *Exp. Neurol.* **237**:355–362. [9]

- Tabuchi, K., J. Blundell, M. R. Etherton, et al. 2007. A Neuroligin-3 Mutation Implicated in Autism Increases Inhibitory Synaptic Transmission in Mice. *Science* **318**(5847):71–76. [2]
- Takahashi, D. Y., D. Z. Narayanan, and A. A. Ghazanfar. 2013. Coupled Oscillator Dynamics of Vocal Turn-Taking in Monkeys. *Curr. Biol.* **23**:2162–2168. [8]
- Takahashi, K., K. Tanabe, M. Ohnuki, et al. 2007. Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors. *Cell* **131**:861–872. [8, 11]
- Takahashi, K., and S. Yamanaka. 2006. Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors. *Cell* **126**:663–676. [8, 11]
- Talpos, J. C., B. D. Winters, R. Dias, L. M. Saksida, and T. J. Bussey. 2009. A Novel Touchscreen Automated Paired-Associate Learning (PAL) Task Sensitive to Pharmacological Manipulation of the Hippocampus: A Translational Rodent Model of Cognitive Impairments in Neurodegenerative Disease. *Psychopharmacology* **205**:157–168. [12]
- Taylor Tavares, J. V., L. Clark, M. L. Furey, et al. 2008. Neural Basis of Abnormal Response to Negative Feedback in Unmedicated Mood Disorders. *NeuroImage* **42**(3):1118–1126. [12]
- Testa-Silva, G., M. B. Verhoog, N. A. Goriounova, et al. 2010. Human Synapses Show a Wide Temporal Window for Spike-Timing-Dependent Plasticity. *Front. Synaptic Neurosci.* **2**:12. [10]
- Teyler, T. J., J. P. Hamm, W. C. Clapp, et al. 2005. Long-Term Potentiation of Human Visual Evoked Responses. *Eur. J. Neurosci.* **21**:2045–2050. [10]
- Thut, G., and A. Pascual-Leone. 2010. A Review of Combined TMS-EEG Studies to Characterize Lasting Effect of Repetitive TMS and Assess Their Usefulness in Cognitive and Clinical Neuroscience. *Brain Topogr.* **22**:219–232. [10]
- Tian, G., and D. Finley. 2012. Cell Biology: Destruction Deconstructed. *Nat. Chem. Biol.* **482**(7384):170–171. [5]
- Toro, R., M. Konyukh, R. Delorme, et al. 2010. Key Role for Gene Dosage and Synaptic Homeostasis in Autism Spectrum Disorders. *Trends Genet.* **26**(8):363–372. [2]
- Toro, R., J. B. Poline, G. Huguët, et al. 2014. Genomic Architecture of Human Neuroanatomical Diversity. *Mol. Psychiatry*: doi: 10.1038/mp.2014.1099. [2]
- Toyomaki, A., I. Kusumi, T. Matsuyama, et al. 2008. Tone Duration Mismatch Negativity Deficits Predict Impairment of Executive Function in Schizophrenia. *Prog. Neuropsychopharmacol. Biol. Psychiatry* **32**:95–99. [10]
- Tremblay, M. E., and A. K. Majewska. 2011. A Role for Microglia in Synaptic Plasticity? *Commun. Integr. Biol.* **4**(2):220–222. [7]
- Tritsch, N. X., J. B. Ding, and B. L. Sabatini. 2012. Dopaminergic Neurons Inhibit Striatal Output through Non-Canonical Release of GABA. *Nature* **490**:262–266. [10]
- Tropea, D., E. Giacometti, N. R. Wilson, et al. 2009. Partial Reversal of Rett Syndrome-Like Symptoms in MeCP2 Mutant Mice. *PNAS* **106**:2029–2034. [10]
- Tulving, E. 1983. Elements of Episodic Memory. Oxford Oxford Univ. Press. [12]
- Turetsky, B. I., M. E. Calkins, G. A. Light, et al. 2007a. Neurophysiological Endophenotypes of Schizophrenia: The Viability of Selected Candidate Measures. *Schizophr. Bull.* **33**:69–94. [10]
- Turetsky, B. I., C. G. Kohler, T. Indersmitten, et al. 2007b. Facial Emotion Recognition in Schizophrenia: When and Why Does It Go Awry? *Schizophr. Res.* **94**:253–263. [10]

- Turner, D. C., L. Clark, and E. Pomarol-Clotet. 2004. Modafinil Improves Cognition and Attentional Set Shifting in Patients with Chronic Schizophrenia. *Neuropsychopharmacology* **29**:1363–1373. [12]
- Tye, K. M., and K. Deisseroth. 2012. Optogenetic Investigation of Neural Circuits Underlying Brain Disease in Animal Models. *Nat. Rev. Neurosci.* **13**(4):251–266. [8]
- Tye, K. M., J. J. Mirzabekov, M. R. Warden, et al. 2013. Dopamine Neurons Modulate Neural Encoding and Expression of Depression-Related Behaviour. *Nature* **493**:537–541. [9]
- Tye, K. M., R. Prakash, S.-Y. Kim, et al. 2011. Amygdala Circuitry Mediating Reversible and Bidirectional Control of Anxiety. *Nature* **471**(7338):358–362. [8]
- Ugurbil, K., J. Xu, E. J. Auerbach, et al. 2013. Pushing Spatial and Temporal Resolution for Functional and Diffusion MRI in the Human Connectome Project. *Neuroimage* **80**:80–104. [9]
- Uhlhaas, P. J., and W. Singer. 2006. Neural Synchrony in Brain Disorders: Relevance for Cognitive Dysfunctions and Pathophysiology. *Neuron* **52**:155–168. [10]
- Umbricht, D., and S. Krljes. 2005. Mismatch Negativity in Schizophrenia: A Meta-Analysis. *Schizophr. Res.* **76**:1–23. [10]
- van de Leemput, I. A., M. Wichers, A. O. Cramer, et al. 2014. Critical Slowing Down as Early Warning for the Onset and Termination of Depression. *PNAS* **111**(1):87–92. [4]
- van den Broeke, E. N., C. M. van Rijn, J. A. Biurrun Manresa, et al. 2010. Neurophysiological Correlates of Nociceptive Heterosynaptic Long-Term Potentiation in Humans. *J. Neurophysiol.* **103**:2107–2113. [10]
- Van Essen, D. C., S. M. Smith, D. M. Barch, et al. 2013. The WU-Minn Human Connectome Project: An Overview. *Neuroimage* **80**:62–79. [7]
- van Os, J., P. Delespaul, J. Wigman, I. Myin-Germeys, and M. Wichers. 2013. Beyond DSM and ICD: Introducing “Precision Diagnosis” for Psychiatry Using Momentary Assessment Technology. *World Psychiatry* **12**(2):113–117. [4]
- Varga, V., A. Losonczy, B. V. Zemelman, et al. 2009. Fast Synaptic Subcortical Control of Hippocampal Circuits. *Science* **326**:449–453. [10]
- Varoqueaux, F., G. Aramuni, R. L. Rawson, et al. 2006. Neuroligins Determine Synapse Maturation and Function. *Neuron* **51**(6):741–754. [2]
- Varrone, A., and C. Halldin. 2012. New Developments of Dopaminergic Imaging in Parkinson’s Disease. *Q. J. Nucl. Med. Mol. Imaging* [7]
- Vellucci, S. V., P. J. Martin, and B. J. Everitt. 1988. The Discriminative Stimulus Produced by Penntylentetrazole: Effects of Systemic Anxiolytics and Anxiogenics. Aggressive Defeat and Midazolam or Muscimol Infused into the Amygdala. *J. Psychopharmacol.* **2**:809–893. [12]
- Verkerk, A. J., M. Pieretti, J. S. Sutcliffe, et al. 1991. Identification of a Gene (FMR-1) Containing a CGG Repeat Coincident with a Breakpoint Cluster Region Exhibiting Length Variation in Fragile X Syndrome. *Cell* **65**(5):905–914. [13]
- Verret, L., E. O. Mann, G. B. Hang, et al. 2012. Inhibitory Interneuron Deficit Links Altered Network Activity and Cognitive Dysfunction in Alzheimer Model. *Cell* **149**(3):708–721. [13]
- Vierbuchen, T., A. Ostermeier, Z. P. Pang, et al. 2010. Direct Conversion of Fibroblasts to Functional Neurons by Defined Factors. *Nature* **463**(7284):1035–1041. [13]
- Vierbuchen, T., and M. Wernig. 2011. Direct Lineage Conversions: Unnatural but Useful? *Nat. Biotechnol.* **29**(10):892–907. [13]

- Vincent, J. L., G. H. Patel, M. D. Fox, et al. 2007. Intrinsic Functional Architecture in the Anaesthetized Monkey Brain. *Nature* **447**:83–86. [9]
- Voineagu, I., X. Wang, P. Johnston, et al. 2011. Transcriptomic Analysis of Autistic Brain Reveals Convergent Molecular Pathology. *Nature* **474(7351)**:380–384. [2]
- Voisine, C., J. S. Pedersen, and R. I. Morimoto. 2010. Chaperone Networks: Tipping the Balance in Protein Folding Diseases. *Neurobiol. Dis.* **40(1)**:12–20. [5]
- Volk, D. W., and D. A. Lewis. 2010. Prefrontal Cortical Circuits in Schizophrenia. *Curr. Top. Behav. Neurosci.* **4**:485–508. [8]
- Voon, V., M. A. Irvine, K. Derbyshire, et al. 2014. Measuring “Waiting” Impulsivity in Substance Addictions and Binge Eating Disorder in a Novel Analogue of Rodent Serial Reaction Time Task. *Biol. Psychiatry* **75**:148–155. [12]
- Voronin, L. L. 1994. Quantal Analysis of Hippocampal Long-Term Potentiation. *Rev. Neurosci.* **5**:141–170. [10]
- Vos, T., A. D. Flaxman, M. Naghavi, et al. 2012. Years Lived with Disability (YLDs) for 1160 Sequelae of 289 Diseases and Injuries 1990–2010: A Systematic Analysis for the Global Burden of Disease Study 2010. *Lancet* **380**:2163–2196. [1]
- Vossel, K. A., A. J. Beagle, G. D. Rabinovici, et al. 2013. Seizures and Epileptiform Activity in the Early Stages of Alzheimer Disease. *JAMA Neurol.* **70(9)**:1158–1166. [6, 13]
- Walker, L. C., M. I. Diamond, K. E. Duff, and B. T. Hyman. 2013. Mechanisms of Protein Seeding in Neurodegenerative Diseases. *JAMA Neurol.* **70**:304–310. [9]
- Wang, D., S. S. El-Amouri, M. Dai, et al. 2013a. Engineering a Lysosomal Enzyme with a Derivative of Receptor-Binding Domain of apoE Enables Delivery across the Blood-Brain Barrier. *PNAS* **110(8)**:2999–3004. [7]
- Wang, H., H. Yang, C. S. Shivalila, et al. 2013b. One-Step Generation of Mice Carrying Mutations in Multiple Genes by CRISPR/Cas-Mediated Genome Engineering. *Cell* **153**:910–918. [9]
- Wang, J., F. Wagner, D. A. Borton, et al. 2012. Integrated Device for Combined Optical Neuromodulation and Electrical Recording for Chronic *in Vivo* Applications. *J. Neural Eng.* **9(1)**:016001. [13]
- Wang, J., X. Zuo, and Y. He. 2010a. Graph-Based Network Analysis of Resting-State Functional MRI. *Front. Syst. Neurosci.* **4**:15. [9]
- Wang, P., Y. Xue, X. Shang, and Y. Liu. 2010b. Diphtheria Toxin Mutant CRM197-Mediated Transcytosis across Blood-Brain Barrier *in vitro*. *Cell. Mol. Neurobiol.* **30(5)**:717–725. [7]
- Wang, W. Y., B. J. Barratt, D. G. Clayton, and J. A. Todd. 2005. Genome-Wide Association Studies: Theoretical and Practical Concerns. *Nat. Rev. Genet.* **6**:109–118. [3]
- Wang, X., P. A. McCoy, R. M. Rodriguiz, et al. 2011. Synaptic Dysfunction and Abnormal Behaviors in Mice Lacking Major Isoforms of Shank3. *Hum. Mol. Genet.* **20(15)**:3093–3108. [4]
- Wang, Y., H.-F. Guo, T. A. Pologruto, et al. 2004. Stereotyped Odor-Evoked Activity in the Mushroom Body of *Drosophila* Revealed by Green Fluorescent Protein-Based Ca²⁺ Imaging. *J. Neurosci.* **24**:6507–6514. [10]
- Ward, N. M., and V. J. Brown. 1996. Covert Orienting of Attention in the Rat and the Role of Striatal Dopamine. *J. Neurosci.* **16**:3082–3088. [12]
- Watson, K. K., and M. L. Platt. 2012. Of Mice and Monkeys: Using Non-Human Primate Models to Bridge Mouse- and Human-Based Investigations of Autism Spectrum Disorders. *J. Neurodev. Disord.* **4(1)**:21. [13]

- Watts, J. C., K. Giles, A. Oehler, et al. 2013. Transmission of Multiple System Atrophy Prions to Transgenic Mice. *PNAS* **110(48)**:19555–19560. [5]
- Wei, F., and M. Zhuo. 2001. Potentiation of Sensory Responses in the Anterior Cingulate Cortex Following Digit Amputation in the Anaesthetised Rat. *J. Physiol.* **532**:823–833. [10]
- Weinberger, D. R. 1987. Implications of Normal Brain Development for the Pathogenesis of Schizophrenia. *Arch. Gen. Psychiatry* **44(7)**:660–669. [3, 13]
- Weiner, I. 2003. The “Two-Headed” Latent Inhibition Model of Schizophrenia: Modeling Positive and Negative Symptoms and Their Treatment. *Psychopharmacology* **169**:257–297. [12]
- Weiss, I. C., A. M. Domeney, C. A. Heidebreder, J. L. Moreau, and J. Feldon. 2001. Early Social Isolation, but Not Maternal Separation, Affects Behavioral Sensitization to Amphetamine in Male and Female Adult Rats. *Pharmacol. Biochem. Behav.* **70(2-3)**:397–409. [13]
- Welch, J. M., J. Lu, R. M. Rodriguiz, et al. 2007. Cortico-Striatal Synaptic Defects and OCD-Like Behaviors in SAPAP3 Mutant Mice. *Nature* **448**:894–900. [8]
- Wichmann, T., H. Bergman, and M. R. DeLong. 1994. The Primate Subthalamic Nucleus. III. Changes in Motor Behavior and Neuronal Activity in the Internal Pallidum Induced by Subthalamic Inactivation in the MPTP Model of Parkinsonism. *J. Neurophysiol.* **72**:521–531. [9]
- Wichmann, T., H. Bergman, P. A. Starr, et al. 1999. Comparison of MPTP-Induced Changes in Spontaneous Neuronal Discharge in the Internal Pallidal Segment and in the Substantia Nigra Pars Reticulata in Primates. *Exp. Brain Res.* **125**:397–409. [9]
- Wichterle, H., I. Lieberam, J. A. Porter, and T. M. Jessell. 2002. Directed Differentiation of Embryonic Stem Cells into Motor Neurons. *Cell* **110**:385–397. [11]
- Wickersham, I. R., S. Finke, K. Conzelmann, and E. M. Callaway. 2007. Retrograde Neuronal Tracing with a Deletion-Mutant Rabies Virus. *Nat. Methods* **4**:47–49. [10]
- Wicks, P., T. E. Vaughan, M. P. Massagli, and J. Heywood. 2011. Accelerated Clinical Discovery Using Self-Reported Patient Data Collected Online and a Patient-Matching Algorithm. *Nat. Biotechnol.* **29(5)**:411–414. [2]
- Wietek, J., J. S. Wiegert, N. Adeishvili, et al. 2014. Conversion of Channelrhodopsin into a Light-Gated Chloride Channel. *Science* **344(6182)**:409–412. [10]
- Williams, H. J., N. Craddock, G. Russo, et al. 2011. Most Genome-Wide Significant Susceptibility Loci for Schizophrenia and Bipolar Disorder Reported to Date Cross-Traditional Diagnostic Boundaries. *Hum. Mol. Genet.* **20(2)**:387–391. [3]
- Willsey, A. J., S. J. Sanders, M. Li, et al. 2013. Coexpression Networks Implicate Human Midfetal Deep Cortical Projection Neurons in the Pathogenesis of Autism. *Cell* **155(5)**:997–1007. [2, 10]
- Wing, J., and J. Nixon. 1975. Discriminating Symptoms in Schizophrenia: A Report from the International Pilot Study of Schizophrenia. *Arch. Gen. Psychiatry* **32(7)**:853–859. [4]
- Winstanley, C. A., D. E. H. Theobald, R. N. Cardinal, and T. W. Robbins. 2004. Contrasting Roles of Basolateral Amygdala and Orbitofrontal Cortex in Impulsive Choice. *J. Neurosci.* **24**:4718–4722. [12]
- Wise, R. 2004. Dopamine, Learning and Motivation. *Nat. Rev. Neurosci.* **5**:483–494. [12]
- Wohr, M., F. I. Rouillet, A. Y. Hung, M. Sheng, and J. N. Crawley. 2011. Communication Impairments in Mice Lacking Shank1: Reduced Levels of Ultrasonic Vocalizations and Scent Marking Behavior. *PLoS One* **6(6)**:e20631. [4]

- Wolf, A. B., J. Valla, G. Bu, et al. 2013. Apolipoprotein E as a Beta-Amyloid-Independent Factor in Alzheimer's Disease. *Alzheimers Res. Ther.* **5(5)**:38. [7]
- Wolters, A., F. Sandbrink, A. Schlottmann, et al. 2003. A Temporally Asymmetric Hebbian Rule Governing Plasticity in the Human Motor Cortex. *J. Neurophysiol.* **89**:2339–2345. [10]
- Wolters, A., A. Schmidt, A. Schramm, et al. 2005. Timing-Dependent Plasticity in Human Primary Somatosensory Cortex. *J. Physiol.* **565**:1039–1052. [10]
- Won, H., H. R. Lee, H. Y. Gee, et al. 2012. Autistic-Like Social Behaviour in Shank2-Mutant Mice Improved by Restoring NMDA Receptor Function. *Nature* **486(7402)**:261–265. [2, 4]
- Wood, S. J., C. Pantelis, T. Proffitt, et al. 2003. Spatial Working Memory Ability Is a Marker of Risk-for-Psychosis. *Psychol. Med.* **33**:1239–1247. [12]
- Wooding, S., A. Pollitt, S. Castle-Clarke, et al. 2013. Mental Health Retrosight. Understanding the Returns from Research (Lessons from Schizophrenia). RAND Corporation. [4]
- Wooten, G. F., and R. C. Collins. 1981. Metabolic Effects of Unilateral Lesion of the Substantia Nigra. *J. Neurosci.* **1**:285–291. [9]
- Worbe, Y., G. Savulich, V. Voon, E. Fernandez-Egea, and T. W. Robbins. 2014. Serotonin Depletion Induces “Waiting Impulsivity” on the Human Four Choice Serial Reaction Time Task: Cross-Species Translational Significance. *Neuropsychopharmacology* **39**:1519–1526. [12]
- Wynn, J. K., C. Sugar, W. P. Horan, R. Kern, and M. F. Green. 2010. Mismatch Negativity, Social Cognition, and Functioning in Schizophrenia Patients. *Biol. Psychiatry* **67**:940–947. [10]
- Xia, C. F., J. Arteaga, G. Chen, et al. 2013. [(18)F]T807, a Novel Tau Positron Emission Tomography Imaging Agent for Alzheimer's Disease. *Alzheimers Dement.* **9(6)**:666–676. [7]
- Xu, W., W. Morishita, P. S. Buckmaster, et al. 2012. Distinct Neuronal Coding Schemes in Memory Revealed by Selective Erasure of Fast Synchronous Synaptic Transmission. *Neuron* **73**:990–1001. [10]
- Yamanaka, S. 2007. Strategies and New Developments in the Generation of Patient-Specific Pluripotent Stem Cells. *Cell Stem Cell* **1**:39–49. [11]
- Yanamandra, K., N. Kfoury, H. Jiang, et al. 2013. Anti-Tau Antibodies That Block Tau Aggregate Seeding *in Vitro* Markedly Decrease Pathology and Improve Cognition *in Vivo*. *Neuron* **80(2)**:402–414. [7]
- Yang, J., B. Benyamin, B. P. McEvoy, et al. 2010. Common SNPs Explain a Large Proportion of the Heritability for Human Height. *Nat. Genet.* **42(7)**:565–569. [2]
- Yang, L., D. Rieves, and C. Ganley. 2012a. Brain Amyloid Imaging: FDA Approval of Florbetapir F18 Injection. *N. Engl. J. Med.* **367(10)**:885–887. [13]
- Yang, M., O. Bozdagi, M. L. Scattoni, et al. 2012b. Reduced Excitatory Neurotransmission and Mild Autism-Relevant Phenotypes in Adolescent Shank3 Null Mutant Mice. *J. Neurosci.* **32(19)**:6525–6541. [4]
- Yang, Y. M., S. K. Gupta, K. J. Kim, et al. 2013. A Small Molecule Screen in Stem-Cell-Derived Motor Neurons Identifies a Kinase Inhibitor as a Candidate Therapeutic for ALS. *Cell Stem Cell* **12**:713–726. [11, 14]
- Yizhar, O., L. E. Fenno, M. Prigge, et al. 2011. Neocortical Excitation/Inhibition Balance in Information Processing and Social Dysfunction. *Nature* **477(7363)**:171–178. [8]
- Yu, D. X., M. C. Marchetto, and F. H. Gage. 2013a. Therapeutic Translation of iPSCs for Treating Neurological Disease. *Cell Stem Cell* **12**:678–688. [11]

- Yu, T. W., M. H. Chahrour, M. E. Coulter, et al. 2013b. Using Whole-Exome Sequencing to Identify Inherited Causes of Autism. *Neuron* **77**(2):259–273. [2]
- Yue, Z., Q. J. Wang, and M. Komatsu. 2008. Neuronal Autophagy: Going the Distance to the Axon. *Autophagy* **4**(1):94–96. [5]
- Zaehle, T., W. C. Clapp, J. P. Hamm, M. Meyer, and I. J. Kirk. 2007. Induction of LTP-Like Changes in Human Auditory Cortex by Rapid Auditory Stimulation: An fMRI Study. *Restor. Neurol. Neurosci.* **25**:251–259. [10]
- Zahs, K. R., and K. H. Ashe. 2010. Too Much Good News: Are Alzheimer Mouse Models Trying to Tell Us How to Prevent, Not Cure, Alzheimer's Disease? *Trends Neurosci.* **33**(8):381–389. [6]
- Zeeb, F. D., T. W. Robbins, and C. A. Winstanley. 2009. Serotonergic and Dopaminergic Modulation of Gambling Behavior as Assessed Using a Novel Rat Gambling Task. *Neuropsychopharmacology* **34**:2329–2343. [12]
- Zhang, F., L. Cong, S. Lodato, et al. 2011. Efficient Construction of Sequence-Specific TAL Effectors for Modulating Mammalian Transcription. *Nat. Biotechnol.* **29**:149–153. [8]
- Zhang, Y., C. Pak, Y. Han, et al. 2013. Rapid Single-Step Induction of Functional Neurons from Human Pluripotent Stem Cells. *Neuron* **78**:785–798. [1, 8, 11]
- Zhao, S., J. T. Ting, H. E. Atallah, et al. 2011. Cell Type-Specific Channelrhodopsin-2 Transgenic Mice for Optogenetic Dissection of Neural Circuitry Function. *Nat. Methods* **8**(9):745–752. [8]
- Zhou, Z., H. Zhu, and L. Chen. 2013. Effect of Aripiprazole on Mismatch Negativity (MMN) in Schizophrenia. *PLoS One* **8**:e52186. [10]
- Zhu, X., A. C. Need, S. Petrovski, and D. B. Goldstein. 2014. One Gene, Many Neuropsychiatric Disorders: Lessons from Mendelian Diseases. *Nat. Neurosci.* **17**(6):773–781. [2]
- Ziemann, U., T. V. Ilić, T. V. Ilić, et al. 2004. Learning Modifies Subsequent Induction of Long-Term Potentiation-Like and Long-Term Depression-Like Plasticity in Human Motor Cortex. *J. Neurosci.* **24**:1666–1672. [10]
- Ziemann, U., W. Paulus, M. A. Nitsche, et al. 2008. Consensus: Motor Cortex Plasticity Protocols. *Brain Stimul.* **1**:164–182. [10]
- Zimmermann, P., M. Gondan, and B. Fimm. 2004. KiTAP Testbatterie zur Aufmerksamkeitsprüfung für Kinder. Freiburg: Psytest. [10]
- Zlokovic, B. V. 2008. The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders. *Neuron* **57**(2):178–201. [7]